

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Welcome to STN International! Enter x:x

LOGINID:sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003  
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:01:50 ON 03 FEB 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:02:00 ON 03 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2003 HIGHEST RN 484598-30-3

DICTIONARY FILE UPDATES: 31 JAN 2003 HIGHEST RN 484598-30-3

TSOA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09815362.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:02:14 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2113 TO ITERATE

47.3% PROCESSED 1000 ITERATIONS 9 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 39504 TO 45016  
PROJECTED ANSWERS: 119 TO 641

L2 9 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:02:17 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 41513 TO ITERATE

100.0% PROCESSED 41513 ITERATIONS 417 ANSWERS  
SEARCH TIME: 00.00.01

L3 417 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 07:02:22 ON 03 FEB 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Feb 2003 VOL 138 ISS 6  
FILE LAST UPDATED: 2 Feb 2003 (20030202/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 33 L3

=> d ibib abs hitstr 1-33

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:754359 CAPLUS

DOCUMENT NUMBER: 137:263032

TITLE: Preparation of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors  
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.; Gomez, Dario G.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076950	A2	20021003	WO 2002-US8222	20020313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CO, CW, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, US 2001-815362 A 20010321				
US 2001-815362 A 20010321				
US 1997-985347 B2 19971204				
US 1998-205597 B2 19981204				
US 1999-329752 B2 19990610				
OTHER SOURCE(S): MARPAT 137:263032				
GI				



AB Comps. (shown as I), which are selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors and useful for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects, are claimed. Also included are methods of making and using such comps. In I, each x is independently 1 or 2; each R1 is independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H1-2. Each R2 and each R3 are


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H; C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H1-2; or an R2 and an R3 together condense to form a satd., partly satd., or unsatd. ring structure having the formula -[C(R6)p]q-Xa-[C(R6)p]r-Xt-[C(R6)p]u where each R6 is independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl and oxo where each p is independently 1 or 2, q is 0-5, r is 0-5, u is 0-5. Each X is independently O, S, or N and a is 0 or 1 provided that q + r + u + s + t < 6. Y is O; S; N; -[C(R7)]s-, where each R7 is independently as previously defined for R1, each t is independently 1-2, and s is 1-3; -CH2-; -CH2CH2-; or Y(CH2)2, where Y is O, N, or S; and the dotted lines in I are optional double bonds, with the proviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsatd., and that if Y is O, N or S, the ring including Y contains at least one said double bond. Intrinsic activities towards .alpha.2A, .alpha.2B, .alpha.2C adrenergic receptors of .apprx.100 of the claimed comps. relative to brimonidine/oxymetazoline are tabulated. Although the methods of prepn. are not claimed, .apprx.100 example prepn. are included.

IT 157058-47-4P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-  
 RL: B5U (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USGS (Uses)  
 (prepn. of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors)

RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



IT 157058-44-1P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-157058-52-1P, 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 157058-55-4P, 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- 226570-89-4P, 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride 226571-02-4P, 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- 226571-05-7P, 1H-Imidazole, 4-[[1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- 226571-13-7P, 1H-Imidazole, 4-[[1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- 226571-14-8P, 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-25-1P, 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- 226571-26-2P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- 226571-35-3P, 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]-


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

226571-36-4P, 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride 226571-37-5P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS

CN 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 157058-55-4 CAPLUS

CN 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS

CN 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-02-4 CAPLUS


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS


CN 1H-Imidazole, 4-[[1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-13-7 CAPLUS

CN 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226571-14-8 CAPLUS

CN 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 226571-25-1 CAPLUS

CN 1H-Imidazole, 4-[[1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-26-2 CAPLUS  
CN 1-(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS  
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS  
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-37-5 CAPLUS  
CN 1-(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:576071 CAPLUS  
DOCUMENT NUMBER: 137:262610  
TITLE: Highly Enantioselective Reformatskii Reaction of Ketones: Chelation-Assisted Enantioface Discrimination  
AUTHOR(S): Ojida, Akio; Yamano, Toru; Taya, Naohiro; Tasaka, Akihiro  
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan  
SOURCE: Organic Letters (2002), 4(18), 3051-3054  
CODEN: ORLEP7; ISSN: 1523-7060  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Highly enantioselective Reformatskii reaction of ketones was accomplished using cinchone alkaloids as chiral ligands. Chelation with the sp<sup>2</sup>-nitrogen adjacent to the reactive carbonyl center contributed to the enantioface discrimination for the high enantioselectivities.

IT 463304-60-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)

RN 463304-60-1 CAPLUS  
CN Methanone, 2-naphthalenyl[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




IT 463304-61-2P 463304-63-4P 463304-73-6P  
463304-74-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)


RN 463304-61-2 CAPLUS  
CN 1H-imidazole-4-propanoic acid, .beta.-hydroxy-.beta.-2-naphthalenyl-1-(triphenylmethyl)-, 1,1-dimethylethyl ester, (.beta.-S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 463304-63-4 CAPLUS

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 226571-57-9P, 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)


RN 226571-57-9 CAPLUS  
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 2-Oxazolidinone, 3-[(3S)-3-hydroxy-3-(1H-imidazol-4-yl)-3-(2-naphthalenyl)-1-oxopropyl]-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463304-73-6 CAPLUS  
CN 1,3-Propanediol, 1-(2-naphthalenyl)-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463304-74-7 CAPLUS  
CN 2-Oxazolidinone, 3-[(3S)-3-hydroxy-3-(2-naphthalenyl)-1-oxo-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 463304-62-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)

RN 463304-62-3 CAPLUS  
CN 1,3-Propanediol, 1-(1H-imidazol-4-yl)-1-(2-naphthalenyl)-, (1S)- (9CI)

L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:391718 CAPLUS

DOCUMENT NUMBER: 136:386117

TITLE: Preparation of 7-aryldihydropyrrolo[1,2-c]imidazol-7-ols and analogs as steroid 17-20-lyase inhibitors  
Tasaka, Akihiro; Hitaka, Takenori; Matsunaga, Nobuyuki; Kusaka, Masami; Adachi, Mari; Aoki, Isao; Ojida, Akiro

INVENTOR(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXK02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040484	A2	20020523	WO 2001-JP10002	20011116
WO 2002040484	A3	20020926		
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AG, BG, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014296	A5	20020527	AU 2002-14296	20011116
PRIORITY APPLN. INFO.: JP 2000-351780 A 20001117				
JP 2001-247618 A 20010817				
JP 2001-336880 A 20011101				
WO 2001-JP10002 W 20011116				

OTHER SOURCE(S): MARPAT 136:386117

GI




AB Title compds. {I; R = (un)substituted aryl; Z = (CH<sub>2</sub>)<sub>1-3</sub>} were prepd. Thus, 1-trityl-1H-imidazole-4-carboxaldehyde was condensed with MeCO<sub>2</sub>Et in the presence of BuLi and the product converted in 2 steps to HOCH<sub>2</sub>CH<sub>2</sub>CHO (R<sub>1</sub> = 1-trityl-1H-imidazole-4-yl) which was cyclized to give 5,6-dihydro-7H-pyrrolo[1,2-c]imidazol-7-one. The latter was arylated by 5-methoxybenzo[b]thiophene to give I [R = 5-methoxybenzo[b]thiophen-2-yl, Z = CH<sub>2</sub>]. Data for biol. activity of I were given.

IT 426219-47-8P 426219-55-8P 426219-56-8P


RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(prepn. of 7-aryldihydropyrrolo[1,2-c]imidazol-7-ols and analogs as steroid 17-20-lyase inhibitors)


RN 426219-47-8 CAPLUS  
CN 2-Naphthalenecarboxamide, N,N-bis[1-methylethyl]-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 426219-55-8 CAPLUS  
CN 1H-imidazole-4-propanoic acid, .beta.-[6-[[bis(1-methylethyl)amino]carbonyl]-2-naphthalenyl]-.beta.-hydroxy-1-(triphenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 426219-56-9 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[[1,3-dihydroxy-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 426219-58-1 CAPLUS  
CN 1H-imidazole-4-propanoic acid, .beta.-[6-[[bis(1-methylethyl)amino]carbonyl]-2-naphthalenyl]-.beta.-hydroxy-1-(triphenylmethyl)-, 1,1-dimethylethyl ester, (.beta.-S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:391704 CAPLUS

DOCUMENT NUMBER: 136:401756

TITLE: Preparation of imidazole derivatives for treatment of

prostate and breast cancer

INVENTOR(S): Taaka, Akihiro; Matsunaga, Nobuyuki; Ojida, Akio;

Kusaka, Masami

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIKX02

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040470	A1	20020523	WO 2001-JP10079	20011119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014320	A5	20020527	AU 2002-14320	20011119
JP 2002241377	A2	20020828	JP 2001-353524	20011119
PRIORITY APPLN. INFO.: JP 2000-353634 A 20001120				
JP 2000-382056 A 20001215				
WO 2001-JP10079 W 20011119				


OTHER SOURCE(S): MARPAT 136:401756

G1




AB The title compds., e.g. I [R is hydrogen or a protecting group; R1 is lower alkyl or cycloalkyl; and ring A is an optionally substituted 5- or 6-membered ring having an amide linkage], are prepd. I are steroid C17-20 lyase inhibitors and are useful in the treatment of prostate and breast cancer. The process for prep. I is disclosed. 7-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one inhibited the biosynthesis of testosterone in rats. Formulations are given.

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-34-7 CAPLUS

CN 3H-Benz[e]isoindol-3-one, 2-ethyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-36-9 CAPLUS

CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 430472-38-1 CAPLUS

CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-39-2 CAPLUS

CN 3H-Benz[e]isoindol-3-one, 2-cyclopropyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


IT 430472-50-7P

RL: IMP (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of imidazole derivs. for treatment of prostate and breast cancer)

RN 430472-50-7 CAPLUS

CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-methyl- (9CI) (CA INDEX NAME)



IT 430472-30-3P 430472-32-5P 430472-34-7P

430472-36-9P 430472-38-1P 430472-39-2P

430472-40-5P 430472-41-6P 430472-42-7P

430472-43-8P 430472-44-9P 430472-45-0P

430472-46-1P 430472-47-2P 430472-48-3P

430472-49-4P 430472-51-8P 430472-52-9P


430472-53-0P

RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of imidazole derivs. for treatment of prostate and breast cancer)

RN 430472-30-3 CAPLUS


CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-32-5 CAPLUS


CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-40-5 CAPLUS

CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 430472-41-6 CAPLUS

CN 3H-Benz[e]isoindol-3-one, 2-(dimethylaminol)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-42-7 CAPLUS


CN Benzo[f]phthalazin-4(1H)-one, 2,3-dihydro-8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-43-8 CAPLUS

CN Benzo[f]phthalazin-4(3H)-one, 8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-44-9 CAPLUS  
CN 1H-Benz[f]isindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-45-0 CAPLUS  
CN 1H-Benz[e]isindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-46-1 CAPLUS  
CN Benzo[g]phthalazin-1(2H)-one, 3,4-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-47-2 CAPLUS  
CN Benzo[g]phthalazin-1(2H)-one, 7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 430472-52-9 CAPLUS  
CN 1H-Imidazole-1-carboxylic acid, 4-[1-(2,3-dihydro-2-methyl-3-oxo-1H-benz[e]isindol-7-yl)-1-hydroxy-2-methylpropyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 430472-53-0 CAPLUS  
CN 3H-Benz[e]isindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 247173-85-8 247174-16-9 337520-93-1  
337521-09-2 337521-12-7 337521-14-9  
337521-16-1 337521-18-3 337521-22-9  
337521-24-1 337521-26-3 337521-83-2  
430472-54-1 430472-55-2 430472-56-3  
430472-57-4 430472-58-5 430472-59-6  
430472-60-9 430472-61-0 430472-62-1  
430472-63-2 430472-64-3 430472-68-8  
430472-70-1 430472-71-2 430472-73-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of imidazole derivs. for treatment of prostate and breast cancer)  
RN 247173-85-9 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 430472-48-3 CAPLUS  
CN 3H-Benz[e]isindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-49-4 CAPLUS  
CN 3H-Benz[e]isindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-51-8 CAPLUS  
CN 3H-Benz[e]isindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-, (-) (9CI) (CA INDEX NAME)

Rotation (-).


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-16-9 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337520-93-1 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-09-2 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-12-7 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-14-9 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-16-1 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-18-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-methyl-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-22-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-hydroxy-7-methyl-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-55-2 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 3-(bromomethyl)-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 430472-56-3 CAPLUS  
CN Methanone, [6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 430472-57-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 430472-58-5 CAPLUS  
CN Methanone, (6-hydroxy-5-methyl-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-24-1 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-26-3 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-83-2 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-54-1 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 1-(bromomethyl)-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-59-6 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 1-methyl-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 430472-60-9 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 1-methyl-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-61-0 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 1-(bromomethyl)-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-62-1 CAPLUS  
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-2-methyl-7-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 430472-63-2 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-64-3 CAPLUS  
CN 2-Naphthalenecarboxamide, 1-formyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-69-8 CAPLUS  
CN 3H-Benz[e]isoidol-3-one, 1,2-dihydro-7-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-70-1 CAPLUS

L4 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:353314 CAPLUS

DOCUMENT NUMBER: 136:365878

TITLE: Methods and compositions for treatment of ocular

neovascularization and neural injury

INVENTOR(S): Burke, James A.; Lin, Ton; Wheeler, Larry A.; De

Vries, Gerald W.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036162	A2	20020510	WO 2001-US46014	20011101
W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, B2, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030567	A5	20020515	AU 2002-30567	20011101
US 2002094998	A1	20020718	US 2001-998718	20011101
PRIORITY APPLN. INFO.: US 2000-244850P P 20001101				
WO 2001-US46014 W 20011101				

AB Methods and compns. for the treatment of ocular neovascularization (CNV) and macular degeneration are disclosed. The invention includes combining laser treatment with administration of a neuroprotectant. Seven pigmented rabbits were dosed with either 0.5 mL 0.2% brimonidine or saline administered in 1 eye of each rabbit. One hour later, the animals were treated with a 10-min i.v. infusion of 0.2 mg/kg verteporfin, then the same eye was irradiated 10 min later in the lower fundus with a 689-nm diode laser at 50 J/cm<sup>2</sup>, 600 mW/cm<sup>2</sup> and a spot size of 1.5 mm. Brimonidine reduced the increase in retinal thickness (subretinal cyst + retinal) in the lesion produced by PDT.

IT 226571-05-7, AGN 795 423773-40-4, AGN 960  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methods and compns. for treatment of ocular neovascularization and neural injury)


RN 226571-05-7 CAPLUS  
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 423773-40-4 CAPLUS  
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN 3H-Benz[e]isoidol-3-one, 1,2-dihydro-7-[1-hydroxy-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)ethyl]-2-methyl]- (9CI) (CA INDEX NAME)



RN 430472-71-2 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-1-[(methylamino)methyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 430472-73-4 CAPLUS  
CN 3H-Benz[e]isoidol-3-one, 1,2-dihydro-7-[1-hydroxy-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:148687 CAPLUS

DOCUMENT NUMBER: 136146981

TITLE:

Investigations on inhibitors of human 17.alpha.-hydroxylase-17,20-lyase and their interactions with the enzyme. Molecular modelling of 17.alpha.-hydroxylase-17,20-lyase, part II

AUTHOR(S):

CORPORATE SOURCE:

Department of Pharmacy, Institute of Pharmaceutical Chemistry, Heinrich Heine-University, Dusseldorf, Germany

SOURCE:

Pharmazie (2001), 56(11), 835-842

PUBLISHER:

CODEN: PHARAT; ISSN: 0031-7144

DOCUMENT TYPE:

Govi-Verlag Pharmazeutischer Verlag

LANGUAGE:

English

AB New methods in treatment of hormone-dependent diseases like prostate or breast cancer have become a major subject in medical and pharmaceutical research. Because of the direct correlation of cancer growth and hormone concn., inhibition of hormone biosynthesis presents a promising strategy in cancer therapy. The key enzyme in androgen biosynthesis is the 17.alpha.-hydroxylase-17,20-lyase a cytochrome P 450 system, which specifically converts gestagens to androgens. Because the 3D-structure of the enzyme is still unknown most recently a ligand-based design was used to gain deeper insights into protein structure and function. In this paper we present mol. modelling studies on compds. acting as competitive inhibitors of the human 17.alpha.-hydroxylase-17,20-lyase. The compds. developed by Hartmann et al. belong to two different structural classes and show a wide range of inhibitory potency. The physico-chem. properties of the mols. were investigated and compared by studying structural flexibility and by calcp. mol. interactions fields. The superimposition of all inhibitors in a low energy conformation yielded in the common pharmacophore. In the second part of the paper individual inhibitors were docked into the active site of the enzyme model of CYP17 developed in our group. The dynamic behavior and stability of the protein-inhibitor-complexes was studied. The protein ligand interactions obsd. in course of the mol. dynamics simulations correspond well with the exptl. data.

IT

157058-47-4

RL: PRP (Properties)


(mol. modeling of human 17.alpha.-hydroxylase-17,20-lyase with

steroidal and non-steroidal inhibitors)

RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthaleneone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-

(9CI) (CA INDEX NAME)



REFERENCE COUNT:

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

The optically active isomer produced has a steroid C17.20 lyase inhibitory activity and is useful as a preventive/remedy for tumors such as prostatic and mammary cancer. Also provided is a novel optical resolver II or III. Thus, 1.0 g (RS)-1-(6,7-dimethoxynaphthalen-2-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (IV) (prepn. given) and 822 mg (-)-8-hydroxy-7,9-dioxo-6-phenyl-8-phosphaspiro[4.5]decan-8-one (V) were dissolved in 21 mL ethanol with heating, stirred at room temp. for 6 h, and filtered to give 670 mg (-)-IV.V salt (99% de) in 74% yield which (665 mg) was added to 150 mg 25% aq. NH3, 30 mL H2O, and 20 mL AcOEt, and stirred at room temp. for 30 min. The org. layer was sepd. and concd. in vacuo to give 368 mg (-)-IV (99% de) in 74% yield.

IT

336102-55-7P 336102-62-6P

RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(process for producing optically active anticancer naphthalene deriv.


and hydroxyphenyldioxaphosphorinane resolving agents)

RN 336102-55-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-

methylthyl)-, (-)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 336102-62-6 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-

methylthyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT 247174-39-6 336102-65-9 336102-70-6

336102-73-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(process for producing optically active anticancer naphthalene deriv.

and hydroxyphenyldioxaphosphorinane resolving agents)

RN 247174-39-6 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-[(diphenylmethylene)amino]-2-

naphthalenyl)-.alpha.-(1-methylthyl)-1-(triphenylmethyl)- (9CI) (CA

INDEX NAME)



L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:319877 CAPLUS

DOCUMENT NUMBER: 134:340525

TITLE:

Process for producing optically active naphthalene derivative and optical resolver therefor

INVENTOR(S):

Aoki, Isao; Adachi, Mari; Kawada, Mitsuru; Yamano, Toru; Taya, Naohiro

PATENT ASSIGNEE(S):

Takeda Chemical Industries, Ltd., Japan

SOURCE:

PCT Int. Appl., 103 pp.

DOCUMENT TYPE:

CODEN: PIXX02

LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030763	A1	20010503	WO 2000-JP7282	20001019
V: AE, AG, AI, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IM, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GU, ML, MR, NE, NG, SN, TD, TG				
AU 2000079499	A5	20010508	AU 2000-79499	20001019
EP 1227085	A1	20020731	EP 2000-969902	20001019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 200117785	A2	20010710	JP 1999-301570	A 19991022
PRIORITY APPL. INFO:			JP 1999-301576	A 19991022
			WO 2000-JP7282	W 20001019

OTHER SOURCE(S):

HARPAT 134:340525

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB

A process for producing an optically active isomer of a compd. represented by formula (I) which comprises: reacting a mixture of naphthalene derivs. represented by formula I (wherein R represents a nitrogenous heterocyclic group; R1 represents hydrogen, a hydrocarbon group, or a mononuclear arom. heterocyclic group; R2 represents hydrogen or lower alkyl; symbol indicates the position of an asym. carbon atom; and R3 to R8 each represents hydrogen, a hydrocarbon group, hydroxy, etc., provided that R7 may be bonded to R6 or R8 to form a ring contg. an oxygen atom) with an optically active isomer of a 2-hydroxy-4-phenyl-1,3,2-dioxaphosphorinan-2-one or arom. ring-fused 2-hydroxy-1,3,2-dioxaphosphorinan-2-one compd. represented by formula (II) or (III), resp. (wherein ring A represents a benzene ring; R10 and R11 each represents hydrogen, a hydrocarbon group, etc., or R10 and R11 in combination represent alkylene; symbol indicates the position of an asym. carbon atom; and rings B and C each represents an arom. ring) to yield salts; sepg. the salts; and then isolating the target

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


336102-65-9 CAPLUS  
2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 336102-70-6 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-


N-methyl- (9CI) (CA INDEX NAME)



RN 336102-73-9 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-

methyl- (9CI) (CA INDEX NAME)



IT 247173-05-3P 247173-20-2P 247173-40-6P

247173-41-7P 247173-54-2P 247173-70-2P

247173-71-3P 247173-72-4P 247174-10-3P

247174-11-4P 247174-12-5P 247174-40-9P

247174-41-0P 247174-69-2P 336102-57-9P

336102-59-1P 336102-61-5P 336102-63-7P

336102-64-8P 336102-66-0P 336102-67-1P


336102-69-3P 336102-71-7P 336102-72-8P

336102-74-0P 336102-75-1P 336102-76-2P


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

337534-07-3P 337534-08-4P 337534-10-8P  
337534-11-9P


RL: RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)  
(process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinane resolving agents)  
RN 247173-05-3 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-20-2 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-41-7 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS  
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

337534-07-3P 337534-08-4P 337534-10-8P  
337534-11-9P


RL: RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)  
(process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinane resolving agents)  
RN 247174-11-4 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-12-5 CAPLUS  
CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 247174-40-9 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-41-0 CAPLUS  
CN Acetamide, N-[6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


337534-07-3P 337534-08-4P 337534-10-8P  
337534-11-9P




RN 247173-70-2 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247173-71-3 CAPLUS  
CN Methanone, (6-methoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 247173-72-4 CAPLUS  
CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247174-10-3 CAPLUS  
CN Methanone, (6-ethoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

337534-07-3P 337534-08-4P 337534-10-8P  
337534-11-9P

RL: RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)  
(process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinane resolving agents)  
RN 247174-69-2 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 336102-57-9 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)-, compd. with (-)-8-hydroxy-6-phenyl-7,9-dioxaspiro[4.5]decane 8-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-56-8  
CHF C13 H17 O4 P


Rotation (-).



CH 2

CRN 336102-55-7  
CHF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).




RN 336102-59-1 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 336102-58-0  
CHF C19 H22 N2 O2

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
Rotation (-).



CH 2  
CRN 98674-91-0  
CHF C11 H13 C12 O4 P


Absolute stereochemistry. Rotation (-).



RN 336102-61-5 CAPLUS  
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (+)-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1  
CRN 336102-60-4  
CHF C19 H21 N3 O2

Rotation (+).




CH 2  
CRN 98674-82-9  
CHF C12 H17 O5 P

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
methylene-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1  
CRN 336102-62-6  
CHF C18 H20 N2 O2

Rotation (-).




CH 2  
CRN 98674-83-0  
CHF C12 H17 O5 P

Absolute stereochemistry. Rotation (-).



RN 336102-66-0 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1  
CRN 336102-65-9  
CHF C20 H22 N2 O3



CH 2

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


Absolute stereochemistry. Rotation (+).



RN 336102-63-7 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (-)-4-(4-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1  
CRN 336102-62-6  
CHF C18 H20 N2 O2

Rotation (-).



CH 2  
CRN 98674-89-6  
CHF C11 H14 C1 O4 P

Rotation (-).




RN 336102-64-8 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CRN 98674-87-4  
CHF C11 H14 C1 O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-67-1 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1  
CRN 336102-65-9  
CHF C20 H22 N2 O3



CH 2  
CRN 98674-90-9  
CHF C11 H13 C12 O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-69-3 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester, compd. with (4S)-4-(2-chlorophenyl)-2-

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-68-2  
CMF C19 H20 N2 O3



CM 2

CRN 98674-86-3  
CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (-).




RN 336102-71-7 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-70-6  
CMF C20 H23 N3 O2




L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 336102-74-0 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-73-9  
CMF C18 H19 N3 O2



CM 2

CRN 98674-90-9  
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (+).



RN 336102-75-1 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 336102-73-9  
CMF C18 H19 N3 O2

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2

CRN 98674-87-4  
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-72-8 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (-)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-70-6  
CMF C20 H23 N3 O2




CM 2

CRN 98674-91-0  
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (-).


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CM 2

CRN 98674-87-4  
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-76-2 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-73-9  
CMF C18 H19 N3 O2




CM 2

CRN 98674-82-9  
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (+).

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337534-07-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (11bR)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphinane 4-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 336102-55-7  
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



CH 2

CRN 39648-67-4  
CMF C20 H13 O4 P




RN 337534-08-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CH 2

CRN 98674-86-3  
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-11-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-62-6  
CMF C18 H20 N2 O2


Rotation (-).



CH 2

CRN 98674-86-3  
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).



IT 336103-01-6P 336103-02-7P 336103-04-9P


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-55-7  
CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).



CH 2

CRN 98674-80-7  
CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-10-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 337534-09-5  
CMF C18 H20 N2 O2

Rotation (-).



L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


336103-06-1P 337534-12-0P  
RI: SPN (Synthetic preparation); PREP (Preparation)  
(process for producing optically active anticancer naphthalene deriv.  
and hydroxyphenyldioxaphosphorinane resolving agents)

RN 336103-01-6 CAPLUS  
CN Cyclohexanecarboxylic acid, 2-(aminocarbonyl)-, (1S,2R)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 336103-00-5  
CMF C8 H13 N O3

Absolute stereochemistry.



CH 2


CRN 247173-41-7  
CMF C19 H22 N2 O3



RN 336103-02-7 CAPLUS  
CN Benzenecarboxylic acid, .alpha.-hydroxy-, (.alpha.S)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 247173-41-7  
CMF C19 H22 N2 O3



CH 2

CRN 17199-29-0

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CNF C8 H8 O3

Absolute stereochemistry. Rotation (+).




RN 336103-04-9 CAPLUS  
 CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CN 1

CRN 336103-03-8  
 CNF C18 H19 N3 O2


Absolute stereochemistry. Rotation (-).



CN 2

CRN 98674-87-4  
 CNF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).




RN 336103-06-1 CAPLUS  
 CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN 2

CRN 50573-41-6  
 CNF C8 H11 N O3 S

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE AE FORMAT

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN 1

CRN 336103-05-0  
 CNF C20 H23 N3 O2


Absolute stereochemistry.



CN 2

CRN 98674-87-4  
 CNF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 337534-12-0 CAPLUS  
 CN Sulfamic acid, [(1S)-1-phenylethyl]-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)


CN 1

CRN 247173-41-7  
 CNF C19 H22 N2 O3




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2001:319876 CAPLUS  
 DOCUMENT NUMBER: 134:340505  
 TITLE: Preparation of imidazol-4-ylmethanols as steroid C17-20 lyase inhibitors  
 INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 166 pp.  
 CODEN: FIXX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030762	A1	20010503	WO 2000-JP7283	20001019
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GE, GR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1222174 A1 20020717 EP 2000-969903 20001019 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2002080458 A2 20020319 JP 2000-327022 20001020 PRIORITY APPLN. INFO.: JP 1999-301556 A 19991022 JP 2000-189728 A 20000620 WO 2000-JP7283 W 20001019 OTHER SOURCE(S): MARPAT 134:340505 G1				




AB Title compds. (I) [wherein R = H or a protecting group; R1 = (cyclo)alkyl;

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 R3 and R5 = H, acyl, halo, or (un)substituted alkyl, hydroxyl, thio, or amino; R4 = (un)substituted aryl, heterocyclic, or carbamoyl; or R3 and R4 form a 5- or 6-membered O-contg. ring; or R4 and R5 form a 5- or 6-membered O-contg. ring; R6 = (halo)alkyl; n = 0-3; or salt thereof, which have an inhibitory activity on steroid C17-20 lyase, were prepd. For example, Me 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate (prepn. given) was deacetylated using NaOH and MeOH in THF, converted to the amide using MeNH<sub>2</sub>, and deprotected using pyridinium chloride to give the imidazolyl naphthalenemethanol 11. 11 inhibited steroid C17-20 lyase with IC50 of 6.1 nM and showed inhibitory activity on testosterone biosynthesis (testosterone concn. of groups of rats receiving test compds. to control groups) of 4.5%. 1 are useful for the prevention and treatment of breast cancer or prostate cancer (no data).  
 IT 247173-41-7P, 1-[6-(7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol] 247173-54-2P, N-[6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl]acetamide  
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate) prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)  
 RN 247173-41-7 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-(7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS  
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




IT 247173-85-9P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthol 247174-16-9P, 1-[6-(tert-Butyldimethylsilyloxy-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol] 247174-41-0P, N-[6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]naphthalen-2-yl]acetamide 336103-03-0P, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337520-93-1P 337520-95-3P 337520-97-5P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthonitrile 337520-99-7P 337521-03-6P,

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 1-chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthol 337521-05-8P 337521-07-0P, Methyl 1-chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 337521-09-2P 337521-12-7P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthol 337521-14-9P 337521-16-1P, Methyl 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthoate 337521-18-3P, 1-[6-(tert-Butyldimethylsilyloxy-7-methyl-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol] 337521-22-9P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-3-methyl-2-naphthol 337521-24-1P 337521-26-3P 337521-28-5P, (6-tert-Butyldimethylsilyloxy-2-naphthyl) (1-trityl-1H-imidazol-4-yl)methanol 337521-31-0P, (6-tert-Butyldimethylsilyloxy-2-naphthyl) (1-trityl-1H-imidazol-4-yl)methanone 337521-33-2P, (6-Hydroxy-2-naphthyl) (1-trityl-1H-imidazol-4-yl)methanone 337521-35-4P 337521-37-6P, Methyl 6-[1-(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthoate 337521-39-8P, N-Methyl-6-[1-(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide 337521-47-0P 337521-51-4P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthol 337521-53-6P 337521-55-8P, Methyl 6-[1-hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthoate 337521-57-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl-1-naphthamide 337521-58-1P 337521-60-5P, 2-Hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide 337521-61-6P, 2-Hydroxy-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-1-naphthamide 337521-62-7P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide 337521-63-8P 337521-64-9P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-1-naphthamide 337521-67-2P, 2-Methyl-1-[6-(phenyl-2-naphthyl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol] 337521-69-4P, 1-[6-(2-Furyl)-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-72-9P, 2-Methyl-1-[6-(2-thienyl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-75-2P 337521-76-3P, 2-Methyl-1-[6-(1H-1,2,3-triazol-4-yl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol] 337521-78-5P, 2-Methyl-1-[6-(1H-1,2,3,4-tetrazol-5-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-80-9P 337521-82-1P, 2-Methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-83-2P, Methyl 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 337521-85-4P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337521-88-7P, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methoxy-2-naphthamide 337521-92-3P, (Naphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)methanol 337521-93-4P, (Naphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)ketone 337521-94-8P, (1H-imidazol-4-yl) (Naphtho[2,1-b]furan-7-yl)ketone 337521-99-0P, (1H-imidazol-4-yl) [naphtho[2,1-b]furan-7-yl]ketone 337522-06-2P, (2,3-Dihydro-1H-benzof[chromen-8-yl) (1-trityl-1H-imidazol-4-yl)methanol 337522-07-3P, (2,3-Dihydro-1H-benzof[chromen-8-yl) (1-trityl-1H-imidazol-4-yl)ketone 337522-08-4P, (2,3-Dihydro-1H-benzof[chromen-8-yl) (1H-imidazol-4-yl)ketone 337522-16-4P, (1,2-Dihydronaphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)methanol 337522-18-6P, (1,2-Dihydronaphtho[2,1-b]furan-7-yl) (1-trityl-1H-imidazol-4-yl)ketone


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 337523-78-1P, 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthaldehyde 337523-80-5P, 1-[5-Chloro-6-(1,3-oxazol-5-yl)-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337523-84-9P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthamide 337523-88-3P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthonitrile 337523-90-7P, 3-Methyl-1-[6-(5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-butanol 337523-92-9P, 3-Methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-butanol 337523-96-3P, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthaldehyde 337523-98-5P, 3-Methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-butanol 337524-02-4P, 1-[6-(4,4-Dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2-naphthyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337524-08-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate) prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)  
 RN 247174-16-9 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-16-9 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-[[1-(1-dimethylethyl)dimethylsilyloxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-38-5 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-bromo-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 247174-39-6 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-[(diphenylmethylene)amino]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-41-0 CAPLUS  
 CN Acetamide, N-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 336103-03-8 CAPLUS  
 CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337520-93-1 CAPLUS  
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337520-95-3 CAPLUS  
 CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337520-97-5 CAPLUS  
 CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337520-99-7 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[5-chloro-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-03-6 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(5-chloro-6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-05-8 CAPLUS  
 CN Methanesulfonic acid, trifluoro-, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-07-0 CAPLUS  
 CN 2-Naphthalenecarboxylic acid, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-09-2 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-12-7 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(6-hydroxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-14-9 CAPLUS  
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-16-1 CAPLUS  
 CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-18-3 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-methyl-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-22-9 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(6-hydroxy-7-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-24-1 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-26-3 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-28-5 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-31-0 CAPLUS  
CN Methanone, [6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-33-2 CAPLUS  
CN Methanone, (6-hydroxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 337521-35-4 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-37-6 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-39-8 CAPLUS  
CN 2-Naphthalenecarboxamide, N-methyl-6-[[1-(triphenylmethyl)-1H-imidazol-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-47-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-[2-methylpropyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-51-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-hydroxy-2-naphthalenyl]-.alpha.-[2-methylpropyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-53-6 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-3-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]butyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-55-8 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-3-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]butyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-57-0 CAPLUS  
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-58-1 CAPLUS  
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-60-5 CAPLUS  
CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-61-6 CAPLUS  
CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-62-7 CAPLUS  
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-63-8 CAPLUS  
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-[(methylamino)carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-64-9 CAPLUS  
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-76-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-[(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-78-5 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-[(1H-tetrazol-5-yl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-80-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-1-(triphenylmethyl)-.alpha.-[6-[(1-(triphenylmethyl)-1H-pyrazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337521-82-1 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-67-2 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-phenyl-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337521-69-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2-furanyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-72-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2-thienyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-75-2 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-83-2 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 337521-85-4 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-88-7 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 337521-92-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-93-4 CAPLUS  
CN Methanone, naphtho[2,1-b]furan-7-yl[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 337521-94-5 CAPLUS  
CN Methanone, 1H-imidazol-4-yl-naphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)




RN 337521-99-0 CAPLUS  
CN Methanone, 1H-imidazol-4-yl-naphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)




RN 337522-06-2 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-19-7 CAPLUS  
CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-26-6 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)- (9CI) (CA INDEX NAME)




RN 337522-27-7 CAPLUS  
CN Methanone, (2,3-dihydronaphtho[2,3-b]furan-6-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-28-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-07-3 CAPLUS  
CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 337522-08-4 CAPLUS  
CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-16-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337522-18-6 CAPLUS  
CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337522-29-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 337522-43-7 CAPLUS  
CN 2-Naphthalenecarboxamide, N-ethyl-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337522-47-1 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 337522-51-7 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-55-1 CAPLUS  
CN 2-Naphthalenecarboxamide, N-butyl-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-59-5 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337522-63-1 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclobutyl-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337522-66-4 CAPLUS  
CN 2-Naphthalenecarboxamide, N-(cyclopropylmethyl)-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337522-68-6 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclopentyl-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-81-3 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 337522-85-7 CAPLUS  
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337522-91-5 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,1-dimethyl- (9CI) (CA INDEX NAME)




RN 337522-96-0 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-70-0 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclohexyl-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337522-73-3 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cycloheptyl-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337522-75-5 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337522-78-8 CAPLUS  
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-01-0 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 337523-04-3 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337523-08-7 CAPLUS  
CN Pyrrolidine, 1-[[6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 337523-14-5 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-18-9 CAPLUS  
CN 2-Naphthalenecarboxamide, N-ethoxy-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 337523-22-5 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 337523-25-8 CAPLUS  
CN 2-Naphthalenecarboxamide, N-(2-hydroxyethyl)-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




RN 337523-29-2 CAPLUS  
CN Glycine, N-[(6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-naphthalenyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337523-43-0 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)-2-propenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-45-2 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-49-6 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[cyclopropylhydroxy[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-53-2 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)-3-butenyl]-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-34-9 CAPLUS  
CN L-Alanine, N-[(6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-37-2 CAPLUS  
CN D-Alanine, N-[(6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-41-8 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337523-55-4 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-59-8 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-3-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-69-0 CAPLUS  
CN 2-Naphthalenecarbonitrile, 1-chloro-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)




RN 337523-71-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[5-chloro-6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-73-6 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[5-chloro-6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN 2-Naphthalenecarboxaldehyde, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-78-1 CAPLUS  
 CN 2-Naphthalenecarboxaldehyde, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337523-80-5 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[5-chloro-6-(5-oxazolyl)-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-84-9 CAPLUS  
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-88-3 CAPLUS

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN 2-naphthalenyl-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337524-02-4 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337534-08-4 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-(7-dimethoxy-2-naphthalenyl)-.alpha.-[1-methylethyl]-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7

CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 98674-80-7


CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-90-7 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[2-methylpropyl]-.alpha.-[6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337523-92-9 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[2-methylpropyl]-.alpha.-[6-[1H-1,2,3-triazol-4-yl]-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-96-3 CAPLUS  
 CN 2-Naphthalenecarboxaldehyde, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)



RN 337523-98-5 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[2-methylpropyl]-.alpha.-[6-(5-oxazolyl)-


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 337521-96-7P, 1-(1H-imidazol-4-yl)-1-[naphtho[2,3-d][1,3]dioxol-6-yl]-2-methyl-1-propanol 337522-45-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl-2-naphthamide 337522-94-8P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl-2-naphthamide 337523-27-0P, Ethyl {[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoyl]amino}acetate 337523-39-4P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl-2-naphthamide 337523-51-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl-2-naphthamide 337523-67-8P, 1-[5-Chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)


RN 337521-96-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-[1-methylethyl]-.alpha.-naphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)



RN 337522-45-9 CAPLUS


CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 337522-94-8 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-27-0 CAPLUS  
CN Glycine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 337523-39-4 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-51-0 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-67-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(5-chloro-6-[1H-1,2,3-triazol-4-yl]-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

methylpropyl]-2-naphthamide 337522-79-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl-2-naphthamide 337522-83-5P, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337522-88-0P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl-2-naphthamide 337522-99-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl-2-naphthamide 337523-03-2P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl-2-naphthamide 337523-06-5P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1-pyridin-2-yl)carbonyl]-2-naphthyl]-1-propanol 337523-11-2P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1,3-thiazol-2-yl)-2-naphthamide 337523-16-7P, N-Ethoxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-20-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropoxy-2-naphthamide 337523-24-7P, N-(2-Hydroxyethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-32-7P 337523-36-1P 337523-47-4P 337523-61-2P, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337523-63-4P, (S)-(-)-N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-65-6P, (S)-(-)-N-Cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-76-9P, 1-[5-Chloro-6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337523-82-7P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methyl-1-methylbutyl]-2-naphthamide 337523-86-1P, 1-(1H-imidazol-4-yl)-3-methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-butanol 337523-94-1P, 1-(1H-imidazol-4-yl)-3-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-butanol 337524-00-2P, 1-[6-(4,4-Dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337524-05-7P


RN 336102-55-7 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 336102-68-2 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 336102-55-7P, (S)-(-)-1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 336102-68-2P, Methyl 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoate 336102-70-6P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-2-naphthamide 336102-73-9P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337521-66-1P, 1-(1H-imidazol-4-yl)-2-methyl-1-(6-phenyl-2-naphthyl)-1-propanol 337521-68-3P, 1-[6-(2-Furyl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337521-70-7P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(2-thienyl)-2-naphthyl]-1-propanol 337521-74-1P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-propanol 337521-77-4P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3,4-tetrazol-5-yl)-2-naphthyl]-1-propanol 337521-79-6P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-pyrazol-4-yl)-2-naphthyl]-1-propanol 337521-81-0P, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-propanol 337521-84-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337521-86-5P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy-2-naphthamide 337521-89-0P, 1-(1H-imidazol-4-yl)-1-(naphtho[2,1-b]furan-7-yl)-2-methyl-1-propanol 337521-95-6P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-00-6P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-09-5P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)ethanol 337522-10-0P, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)propanol 337522-12-0P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-ethanol 337522-21-1P, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-propanol 337522-31-3P 337522-33-5P, (-)-N-(6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl)acetamide 337522-40-4P 337522-41-5P, N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-49-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropyl-2-naphthamide 337522-53-9P, N-Butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-57-3P, N-Cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-61-9P, N-Cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-64-2P, N-Cyclopropylmethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-67-5P, N-Cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-69-7P, N-Cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-72-2P, N-Cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-74-4P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-77-7P, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 336102-70-6 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 336102-73-9 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-66-1 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-phenyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-68-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-(2-furanyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-70-7 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2-thienyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-74-1 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337521-77-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-tetrazol-5-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 337521-79-6 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-pyrazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-95-6 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-(1-methylethyl)-] (9CI) (CA INDEX NAME)



RN 337522-00-6 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)-] (9CI) (CA INDEX NAME)




RN 337522-09-5 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]pyran-8-yl)-.alpha.-methyl-] (9CI) (CA INDEX NAME)




RN 337522-10-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]pyran-8-yl)-.alpha.-ethyl-] (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-81-0 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-84-3 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-86-5 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 337521-89-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-naphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 337522-12-0 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-methyl-] (9CI) (CA INDEX NAME)



RN 337522-21-1 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-ethyl-] (9CI) (CA INDEX NAME)




RN 337522-31-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-ethyl-] (9CI) (CA INDEX NAME)

CH 1

CRN 336102-55-7  
CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).



L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CM 2  
CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



RN 337522-33-5 CAPLUS  
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 337522-40-4 CAPLUS  
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1  
CRN 337522-33-5  
CMF C19 H21 N3 O2


Rotation (-).




CM 2  
CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-61-9 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-64-2 CAPLUS  
CN 2-Naphthalenecarboxamide, N-(cyclopropylmethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-67-5 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-69-7 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-41-5 CAPLUS  
CN 2-Naphthalenecarboxamide, N-ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-49-3 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-53-9 CAPLUS  
CN 2-Naphthalenecarboxamide, N-butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-57-3 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337522-72-2 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-74-4 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-77-7 CAPLUS  
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337522-79-9 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 337522-83-5 CAPLUS  
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-88-0 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl- (9CI) (CA INDEX NAME)



RN 337522-99-3 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 337523-03-2 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337523-06-5 CAPLUS  
CN Pyrrolidine, 1-[[6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-32-7 CAPLUS  
CN L-Alanine, N-[[6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-36-1 CAPLUS  
CN D-Alanine, N-[[6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-47-4 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[(cyclopropylhydroxy-1H-imidazol-4-ylmethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-61-2 CAPLUS


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-11-2 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 337523-16-7 CAPLUS  
CN 2-Naphthalenecarboxamide, N-ethoxy-6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337523-20-3 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 337523-24-7 CAPLUS  
CN 2-Naphthalenecarboxamide, N-(2-hydroxyethyl)-6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337523-63-4 CAPLUS  
CN 2-Naphthalenecarboxamide, N-ethyl-6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-63-4 CAPLUS  
CN 2-Naphthalenecarboxamide, N-ethyl-6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-65-6 CAPLUS  
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-76-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[5-chloro-6-(5-oxazolyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-82-7 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]- (9CI) (CA INDEX NAME)



RN 337523-86-1 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-{1H-1,2,3-triazol-4-yl}-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337523-94-1 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-{5-oxazolyl}-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337524-00-2 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-{5-oxazolyl}-2-naphthalenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-97-1 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337524-05-7 CAPLUS  
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8  
CMF C18 H19 N3 O2


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



IT 247174-44-3, 6-[(1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthaldehyde 337522-97-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 247174-44-3 CAPLUS  
CN 2-Naphthalenecarboxaldehyde, 6-[(1-hydroxy-2-methyl-1-[(1-triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:85068 CAPLUS  
DOCUMENT NUMBER: 134:260881  
TITLE: Potential Antidepressants Displayed Combined  
alpha.2-Adrenoceptor Antagonist and Monoamine Uptake  
Inhibitor Properties  
AUTHOR(S): Cordi, Alex A.; Berque-Bestel, Isabelle; Persigand,  
Thierry; Lacomte, Jean-Michel; Newman-Tancredi,  
Adrian; Audinot, Valerie; Millan, Mark J.  
CORPORATE SOURCE: Institut de Recherches Servier, Suresnes, F-92150, Fr.  
SOURCE: Journal of Medicinal Chemistry (2001), 44(5), 787-805  
CODEN: JMCMAH; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Classical antidepressants are thought to act by raising monoamine (serotonin and noradrenaline) levels in the brain. This action is generally accomplished either by inhibition of monoamine metab. (MAO inhibitors) or by blockade of monoamine uptake (tricyclic antidepressants and selective serotonin or noradrenaline reuptake inhibitors). However, all such agents suffer from a time lag (3-6 wk) before robust clin. efficacy can be demonstrated. This delay may reflect inhibitory actions of noradrenaline at presynaptic .alpha.2A-adrenergic auto- or heteroreceptors which gradually down-regulate upon prolonged exposure. Blockade of presynaptic .alpha.2A-adrenoceptors by an antagonist endowed with monoamine uptake inhibition properties could lead to new antidepressants with greater efficacy and a shorter time lag. In the literature, only two mols. have been described with such a pharmacol. profile. Of these, naphazoline was chosen as a point of departure for the design of 4(5)-[(3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydroimidazole, which displayed the desired profile: .alpha.2A-adrenoceptor antagonist properties and serotonin/noradrenaline uptake inhibition. From this original mol., a series of derivs. was designed and synthesized, encompassing substituted as well as rigid analogs. Structure-activity relationships permitted the selection of 4(5)-[(5-fluorindan-2-yl)methyl]-4,5-dihydroimidazole as a development candidate.


IT 331992-77-9P 331992-78-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and structure-activity relations of potential antidepressants displaying combined .alpha.2-adrenoceptor antagonist and monoamine uptake inhibitor activities)

RN 331992-77-9 CAPLUS  
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 331992-78-0 CAPLUS  
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:12424 CAPLUS

DOCUMENT NUMBER: 134:86245

TITLE: Preparation of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors.  
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA  
 SOURCE: PCT Int. Appl., 145 pp.

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000586	A1	20010104	WO 2000-US15795	20000608
W: AE, AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1104407	A1	20010606	EP 2000-939699	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002156076	A1	20021024	US 2001-948001	20010906
PRIORITY APPL. INFO.: US 1999-329752 A 19990610				
US 1997-985347 B2 19971204				
US 1998-205597 B2 19981204				
US 2000-US15795 W 20000608				
US 2000-679919 A1 20001005				

OTHER SOURCE(S): MARPAT 134:86245  
 GI



AB Title compds. [I: dotted lines = optional double bonds; R = H, alkyl; X = S, CHR1; R1 = H, alkyl, null; Y = O, N, S, [C(R1)n]y, CH:CH, Y1CH2; y = 1-3; n = 1, 2; R2 = H, alkyl, halo, OH, alkoxy, alkenyl, acyl, alkynyl, etc.; R3, R4 = H, alkyl, halo, alkenyl, acyl, alkynyl, etc.; R3R4 = atoms to form (unsatd.) (heterocyclic) ring], were prepd. Thus, 1-(dimethylsulfamoyl)imidazole in THF at -78.degree. was treated with BuLi and tert-butyldimethylsilyl chloride followed by warming to room temp., stirring overnight, cooled to -20.degree., and treatment with BuLi and


L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

3-thiophenecarboxaldehyde followed by warming to room temp. and stirring overnight to give 2-(tert-butyldimethylsilyl)-5-(hydroxythiophen-2-ylmethyl)imidazole-1-sulfonic acid dimethylamide. This was treated sequentially with BuNF, Et3SiH/CF3CO2H/CH2Cl2, and aq. HCl to give 4(5)-thiophen-3-ylmethyl-1H-imidazole. Tested I as eyedrops at 0.03-1% reduced intraocular pressure in cynomolgus monkeys by 12.4-33% and showed no sedative activity.

IT 157058-47-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-47-4 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-55-4P 226570-89-4P 226571-02-4P


226571-05-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-55-4 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226570-89-4 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 226571-02-4 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (CA INDEX NAME)



IT 157058-44-1 157058-52-1 226571-13-7


226571-14-8 226571-25-1 226571-26-2

226571-35-3 226571-36-4 226571-37-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-44-1 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-13-7 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-14-8 CAPLUS  
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226571-25-1 CAPLUS  
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-26-2 CAPLUS  
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-4-methyl]- (9CI) (CA INDEX NAME)




RN 226571-35-3 CAPLUS  
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-36-4 CAPLUS  
CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-37-5 CAPLUS  
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1H-imidazol-4-ylmethyl)-7-methyl]- (9CI) (CA INDEX NAME)



IT 226571-57-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)  
RN 226571-57-9 CAPLUS  
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[(1H-imidazol-4-ylmethyl)-7-methoxy]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:911226 CAPLUS  
DOCUMENT NUMBER: 134:56671  
TITLE: Process for the preparation of 4-alkanoylimidazole derivatives and 1-(2-naphthyl)-1-(1H-imidazol-4-yl)alkanol derivatives  
INVENTOR(S): Kawakami, Jun-ichi  
PATENT ASSIGNER(S): Takeda Chemical Industries, Ltd., Japan  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078727	A1	20001228	WO 2000-JP4036	20000621
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GN, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG JP 2001064264 A2 20010313 JP 2000-191081 20000621 EP 1193258 A1 20020403 EP 2000-940770 20000621 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO PRIORITY APPLN. INFO.: JP 1999-175070 A 19990622 WO 2000-JP4036 V 20000621 OTHER SOURCE(S): CASREACT 134:56671; MARPAT 134:56671 GI				




AB An industrially advantageous process for the prepn. of compds. of general formula (I); wherein the ring A is an optionally substituted imidazole ring; R is an optionally substituted hydrocarbon group or a heterocyclic

L4 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 group; and R1, R2, R3, R4, R5, R6, and R7 are each hydrogen, optionally substituted hydrocarbyl, OH, SH, NH2, acyl, halogeno, or the like)  
 comprises addn. reaction of 4-cyanoimidazole (III; the ring A is same as above) with R-M1 (R is same as above; M1 = alkali metal, Mg-Y1; Y1 = halo) to give 4-acylimidazole (III; R and ring A are same as above), followed by addn. reaction of III with naphthalene alkali metals (IV; R1 - R7 are = same as above; M2 is alkali metal, Mg-Y2; Y2 is halo). This process is reduced in the no. of steps, attains a high yield, and dispenses with the use of a heavy metal compd. The compds. I exhibit a steroid C17-C20 lyase inhibitory activity (no data). Thus, a soln. of 42.7 g 4-cyanoimidazole in 500 mL THF was added dropwise to a 1.1 M soln. of isopropylmagnesium bromide in THF (1.4 L) over a period of 30 min, stirred at 15-25.degree., treated dropwise with 101 aq. H2SO4, stirred for 30 min, neutralized to pH 9 with 30 aq. NaOH, and extd. with EtOAc (300 L .times. 2) to give 82% 1-(1H-imidazol-4-yl)-2-methyl-1-propanone (V). 2-Bromo-6-methoxynaphthalene (5.15 g) was added dropwise to a mixt. of 0.55 g and 3 mg iodine in THF at 50.degree. and stirred at 15-25.degree. for 1.5 h, followed by adding dropwise a soln. of 1 g V in THF, and the resulting mixt. was stirred at 15-25.degree. for 8 h to give, after workup, 84% 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropanol.

IT 247173-05-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of 4-alkanoylimidazole derivs. and .alpha.-(2-naphthyl)-.alpha.-(1H-imidazolyl)alcohol derivs. by addn. reaction of cyanoimidazoles with alkylmagnesium bromides followed by naphthylmagnesium bromide)


RN 247173-05-3 CAPLUS  
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1999:691084 CAPLUS  
 DOCUMENT NUMBER: 131:299449  
 TITLE: Preparation of azolymethylnaphthalenes and related compounds as steroid C17,20-lyase inhibitors.  
 INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 131 pp.  
 CODEN: PIKX02  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954309	A1	19991028	WO 1999-JP2143	19990422
V: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LA, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2328973	AA	19991028	CA 1999-2328973	19990422
JP 2000007658	A2	20000111	JP 1999-114358	19990422
EP 1073640	A1	20010207	EP 1999-917102	19990422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.: JP 1998-113801 A 19980423 WO 1999-JP2143 W 19990422				
OTHER SOURCE(S): MARPAT 131:299449				
GI				




AB Title compds. [I; A1 = (substituted) imidazolyl, thiazolyl, oxazolyl, pyridyl; R11 = H, (substituted) hydrocarbyl, monocyclic heteroaryl; R21 = H, (substituted) alkyl; R3-R9 = H, (substituted) hydrocarbyl, OH, SH, amino, acyl, halo; R21 = (substituted) alkyl], and salts or prodrugs thereof, were prepd. Thus, 2-bromo-6-methoxynaphthalene in THF at -78.degree. was treated with BuLi and then with 4-formyl-1-trityl-1H-imidazole to give (6-methoxynaphthalen-2-yl)(1-trityl-1H-imidazol-4-yl)methanol. The product was refluxed with MnO2 in CHCl3 to give the ketone, which was deprotected with HCOOH in THF to give (1H-imidazol-4-yl)(6-methoxynaphthalen-2-yl) ketone. The latter in THF at

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 -10.degree. was treated with Me2CHMgBr in THF to give 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methyl-1-propanol. This inhibited rat steroid C17,20-lyase with IC50 = 33 nM. 1 drug formulations are given.  
 IT 247173-05-3P 247173-06-4P 247173-07-5P  
 247173-09-7P 247173-11-1P 247173-12-2P  
 247173-13-3P 247173-14-4P 247173-17-7P  
 247173-18-8P 247173-19-9P 247173-20-2P  
 247173-21-3P 247173-22-4P 247173-23-5P  
 247173-24-6P 247173-25-7P 247173-26-8P  
 247173-27-9P 247173-28-0P 247173-29-1P  
 247173-30-4P 247173-31-5P 247173-32-6P  
 247173-33-7P 247173-34-8P 247173-35-9P  
 247173-36-0P 247173-37-1P 247173-38-2P  
 247173-39-3P 247173-40-6P 247173-41-7P  
 247173-42-8P 247173-43-9P 247173-44-0P  
 247173-45-1P 247173-46-2P 247173-47-3P  
 247173-48-4P 247173-49-5P 247173-50-6P  
 247173-51-9P 247173-52-0P 247173-53-1P  
 247173-54-2P 247173-55-3P 247173-56-4P  
 247173-57-5P 247173-58-6P 247173-59-7P  
 247173-60-0P 247173-61-1P 247173-62-2P  
 247173-63-3P 247173-64-4P 247173-65-5P  
 247173-66-6P 247173-68-8P 247173-69-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of azolymethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)

RN 247173-05-3 CAPLUS  
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-06-4 CAPLUS  
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 247173-07-5 CAPLUS  
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 247173-09-7 CAPLUS  
 CN 1H-Imidazole-4-methanol, .alpha.-cyclopropyl-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CH 1


CRN 247173-08-6  
 CHF C18 H18 N2 O2



CH 2

CRN 110-17-8  
 CHF C4 H4 O4


Double bond geometry as shown.



RN 247173-11-1 CAPLUS  
 CN 1H-Imidazole-4-methanol, .alpha.-(1,1-dimethylethyl)-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 247173-10-0  
 CHF C19 H22 N2 O2




CH 2


CRN 110-17-8  
 CHF C4 H4 O4

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


Double bond geometry as shown.




RN 247173-12-2 CAPLUS  
CN 3-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-13-3 CAPLUS  
CN 4-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-14-4 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 247173-17-7 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(5-fluoro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-22-4 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-23-5 CAPLUS  
CN 1H-Imidazole-1,4-dimethanol, .alpha.4-(6-hydroxy-2-naphthalenyl)-.alpha.4-(1-methylethyl)-, .alpha.1-acetate (9CI) (CA INDEX NAME)



RN 247173-24-6 CAPLUS  
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 247173-25-7 CAPLUS  
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 247173-26-8 CAPLUS


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-18-8 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-ethyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-19-9 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 247173-20-2 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)




RN 247173-21-3 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-cyclopentyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN 1H-Imidazole, 4-[methoxy(6-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 247173-27-9 CAPLUS  
CN 1H-Imidazole, 4-[(6-methoxy-2-naphthalenyl)(1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 247173-28-0 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-29-1 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-30-4 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[5-[1-[(1,1-dimethylethyl)dimethylalyl]oxy]ethyl]-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 247173-31-5 CAPLUS  
CN 1,6-Naphthalenedimethanol, .alpha.-6-1H-imidazol-4-yl-2-methoxy-.alpha.1-methyl-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-32-6 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-33-7 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(1-methylethenyl)-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-38-2 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 247173-39-3 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-(2-methoxyethoxy)-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-ethoxy-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-41-7 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6,7-dimethoxy-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-42-8 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-methyl-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-34-8 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(1-methylethyl)-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-35-9 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-, [[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]oxy]methyl ester (9CI) (CA INDEX NAME)




RN 247173-36-0 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-(1-methylethoxy)-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-37-1 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-(1-methylethyl)-2-naphthalenyl]-.alpha.-[6-propoxy-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-43-9 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[5,6-dimethoxy-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-44-0 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-hydroxy-7-methoxy-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-45-1 CAPLUS  
CN 1,6-Naphthalenedimethanol, .alpha.-6-1H-imidazol-4-yl-2-methoxy-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-46-2 CAPLUS  
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(methoxymethyl)-2-naphthalenyl]-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-47-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(5-ethyl-6-methoxy-2-naphthalenyl)-  
.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-48-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(5-ethenyl-6-methoxy-2-naphthalenyl)-  
.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-49-5 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(5-bromo-6-methoxy-2-naphthalenyl)-  
.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-50-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-(fluoromethoxy)-2-naphthalenyl)-  
.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-55-3 CAPLUS  
CN Urea, N'-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 247173-56-4 CAPLUS  
CN Urea, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-  
N'-methyl- (9CI) (CA INDEX NAME)




RN 247173-57-5 CAPLUS  
CN Methanesulfonamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-58-6 CAPLUS  
CN 2,6-Naphthalenedimethanol, .alpha.-(1H-imidazol-4-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-51-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-5,7-dimethyl-2-naphthalenyl)-  
.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-52-0 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-53-1 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS  
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247173-59-7 CAPLUS  
CN Ethanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-60-0 CAPLUS  
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-61-1 CAPLUS  
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 247173-62-2 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-ethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-63-3 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-methyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-64-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-ethynyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-65-5 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-methylthio-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-66-6 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-1-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-68-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-propyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-71-3 CAPLUS  
CN Methanone, (6-methoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 247173-72-4 CAPLUS  
CN Methanone, 1H-imidazol-4-yl[6-methoxy-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-73-5 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-methyl-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-74-6 CAPLUS  
CN 3-Pyridinemethanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 247173-69-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1-methylethyl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 247174-67-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of azolymethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)  
RN 247174-67-0 CAPLUS  
CN Methanone, (5-fluoro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




IT 247173-70-2P 247173-71-3P 247173-72-4P  
247173-73-5P 247173-74-6P 247173-75-7P  
247173-76-8P 247173-81-5P 247173-82-6P  
247173-83-7P 247173-85-9P 247173-86-0P  
247173-88-2P 247173-89-3P 247173-90-6P  
247173-92-8P 247173-93-9P 247173-94-0P  
247173-95-1P 247173-98-4P 247173-99-5P  
247174-00-1P 247174-01-2P 247174-03-4P  
247174-04-5P 247174-05-6P 247174-06-7P  
247174-07-8P 247174-08-9P 247174-09-0P  
247174-10-3P 247174-11-4P 247174-12-5P  
247174-16-9P 247174-17-0P 247174-24-9P  
247174-25-0P 247174-26-1P 247174-29-4P  
247174-31-8P 247174-35-2P 247174-36-3P  
247174-38-5P 247174-39-6P 247174-40-9P  
247174-41-0P 247174-42-1P 247174-43-2P  
247174-44-3P 247174-45-4P 247174-46-5P  
247174-47-6P 247174-48-7P 247174-50-1P  
247174-51-2P 247174-52-3P 247174-54-5P  
247174-63-6P 247174-64-7P 247174-65-8P  
247174-66-9P 247174-69-2P 247174-72-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of azolymethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)  
RN 247173-70-2 CAPLUS


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-75-7 CAPLUS  
CN 4-Pyridinemethanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 247173-76-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-81-5 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-(6-(phenylmethoxy)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-82-6 CAPLUS  
CN Methanone, [6-(phenylmethoxy)-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(triphenylmethyl)-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 247174-05-6 CAPLUS  
CN Methanone, 1H-imidazol-4-yl[6-methoxy-5-(1-methylethenyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247174-06-7 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-, [[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]oxy]methyl ester (9CI) (CA INDEX NAME)




RN 247174-07-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-(1-methylethoxy)-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


247174-08-9 CAPLUS  
CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 247174-09-0 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-(2-methoxyethoxy)-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-10-3 CAPLUS  
CN Methanone, (6-ethoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 247174-11-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-ethoxy-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-12-5 CAPLUS  
CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-16-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-17-0 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247174-24-9 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-25-0 CAPLUS  
CN Methanone, 1H-imidazol-4-yl[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-26-1 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247174-29-4 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[5-ethenyl-6-methoxy-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-31-8 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-(fluoromethoxy)-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-35-2 CAPLUS  
CN 1H-imidazole-4-methanol, .alpha.-[6-methoxy-5,7-dimethyl-2-naphthalenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-36-3 CAPLUS  
 CN Methanone, 1H-imidazol-4-yl-[6-methoxy-5,7-dimethyl-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-38-5 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-39-6 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-[6-[(diphenylmethylene)amino]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-40-9 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-41-0 CAPLUS


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-46-5 CAPLUS  
 CN Ethanone, 1-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247174-47-6 CAPLUS  
 CN 1-Propanone, 1-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-48-7 CAPLUS  
 CN 1-Propanone, 1-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 247174-50-1 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethenyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


CN Acetamide, N-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-42-1 CAPLUS  
 CN Urea, N'-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 247174-43-2 CAPLUS  
 CN Methanesulfonamide, N-[6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-44-3 CAPLUS  
 CN 2-Naphthalenecarboxaldehyde, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 247174-45-4 CAPLUS  
 CN 2,6-Naphthalenedimethanol, .alpha.-(1-methylethyl)-.alpha.-[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-51-2 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-52-3 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-methyl-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-54-5 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(6-ethynyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-63-6 CAPLUS  
 CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(2-propenyl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-64-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propyl-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-65-8 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-(1-methylethenyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-66-9 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1-methylethenyl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-69-2 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-72-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propoxy-2-

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:375530 CAPLUS

DOCUMENT NUMBER: 131:19013

TITLE: Preparation of .alpha.2B and .alpha.2C adrenoceptor agonists

INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 121 pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928300	A1	19990610	WO 1998-US25669	19981203
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, HP, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TG				
CA 2312334	A1	19990610	CA 1998-2312334	19981203
AU 9918025	A1	19990616	AU 1999-18025	19981203
AU 744798	B2	20020307		
EP 1036065	A1	20000920	EP 1998-962883	19981203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9813381	A	20001003	BR 1998-13381	19981203
JP 2001524542	T2	20011204	JP 2000-523194	19981203
NO 2000002773	A	20000802	NO 2000-2773	20000530
US 2002156076	A1	20021024	US 2001-948001	20010906
PRIORITY APPLN. INFO.:				
US 1997-985347 A 19971204				
WO 1998-US25669 W 19981203				
US 1998-205597 B2 19981204				
US 1999-329752 B3 19990610				
US 2000-679919 A1 20001005				

OTHER SOURCE(S): MARPAT 131:19013


AB Title compds. of diverse structural type were prepd. Thus, 7-methoxy-1-tetralone was condensed with 1-dimethylsulfonyl-2-tert-butylidimethylsilyl-5-imidazolecarboxaldehyde (prepn. given) and the product converted in 3 steps to 4(5)-(7-methoxy-1,2,3,4-tetrahydronaphth-2-ylmethyl)-1H-imidazole. Data for biol. activity of title compds. were given.

IT 157058-44-1P 157058-47-4P 157058-52-1P  
157058-55-4P 226570-89-4P 226571-02-4P  
226571-05-7P 226571-13-7P 226571-14-8P  
226571-25-1P 226571-26-2P 226571-35-3P  
226571-36-4P 226571-37-5P 226571-43-3P  
226571-55-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


REFERENCE COUNT: 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
INDEX NAME)


RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS

CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 157058-55-4 CAPLUS

CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS


CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 226571-02-4 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-13-7 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-14-8 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-25-1 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-26-2 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-36-4 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-37-5 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 226571-43-3 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-55-7 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CH 1


CRN 226571-05-7  
 CMF C14 H20 N2



CH 2

CRN 110-17-8  
 CMF C4 H4 O4


Double bond geometry as shown.



IT 226571-57-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)

RN 226571-57-9 CAPLUS  
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:244636 CAPLUS

DOCUMENT NUMBER: 130:252360

TITLE: Preparation of dihydronaphthalene compounds

INVENTOR(S): Hartmann, Rolf Wolfgang; Wachall, Bertil; Yoshihama, Makoto; Nakakoshi, Masamichi; Nomoto, Shin; Ikeda, Yoshikazu

PATENT ASSIGNEE(S): Yukiijirushi Myugyo Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918075	A1	19990415	WO 1998-JP4426	19981001
W: AU, CA, CN, FI, HU, IL, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9808954	A	19990412	ZA 1998-8954	19981001
AU 9892810	A1	19990427	AU 1998-92810	19981001
AU 743405	B2	20020124		
EP 1028110	A1	20000816	EP 1998-945556	19981001
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
FI 2000000207	A	20000201	FI 2000-207	20000201
NO 2000001289	A	20000310	NO 2000-1289	20000310
US 2002032211	A1	20020314	US 2001-866179	20010525

PRIORITY APPLN. INFO.: JP 1997-284263 A 19971002  
WO 1998-JP4426 W 19981001  
US 1999-424126 B1 19991117

OTHER SOURCE(S): MARPAT 130:252360

G1



AB Dihydronaphthalene compds. I (R1 = H, OH, alkyloxy; R2 = alkyl, aralkyl, Ph; R3 = alkyl, Ph, pyridyl, imidazolyl), useful as 17.alpha.-hydroxylase/C17-20-lyase inhibitors, thromboxane A2 synthesis inhibitors, and aromatase inhibitors, were prepd. I (R1 = H, R2 = Me, R3 = 3-pyridyl) showed 17.alpha.-hydroxylase/C17-20-lyase and aromatase inhibitor activity.


IT 157058-45-2P 157058-46-3P 157058-47-4P

221651-52-1P 221651-54-3P 221651-56-5P

221651-61-2P 221651-64-5P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of dihydronaphthalenes)

L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 221651-56-5 CAPLUS

CN 1(2H)-Naphthalenone, 7-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)


RN 221651-61-2 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-propoxy-(9CI) (CA INDEX NAME)



RN 221651-64-5 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-(2-methylpropoxy)-(9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 157058-45-2 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy-(9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy-(9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-(9CI) (CA INDEX NAME)



RN 221651-52-1 CAPLUS

CN 1(2H)-Naphthalenone, 5-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)



RN 221651-54-3 CAPLUS

CN 1(2H)-Naphthalenone, 6-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:543217 CAPLUS

DOCUMENT NUMBER: 129:149262

TITLE: Preparation and biological activity of imidazopyridindole and imidazopyridobenzothiophene combinatorial libraries

INVENTOR(S): Ostresh, John M.

PATENT ASSIGNEE(S): Trega Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXX02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834112	A1	19980806	WO 1997-US22286	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, NG, SN, TD, TG				
US 5856107	A	19990105	US 1997-794364	19970204
AU 9853740	A1	19980825	AU 1998-53740	19971205

PRIORITY APPLN. INFO.: US 1997-794364 19970204  
WO 1997-US22286 19971205


OTHER SOURCE(S): MARPAT 129:149262

G1




AB The invention provides a rapid approach for combinatorial synthesis and screening of libraries of imidazopyridindole and imidazopyridobenzothiophenes I [R1 = H, halo, (un)protected OH, amino, (un)protected carboxy; R2 = H, (un)substituted C1-10 alkyl, (un)substituted Ph, (un)substituted C7-16 phenylalkyl, (un)substituted C3-7 cycloalkyl, (un)substituted naphthyl; R3 = (un)substituted C1-10 alkyl, (un)substituted C2-10 alkenyl, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted C7-16 phenylalkyl, (un)substituted naphthyl, (un)substituted heterocycle; X = H, S; Y = H, Me]. The present invention further provides methods of prep. the libraries and the individual compds. made by the combinatorial synthesis. Reactivity ratios for amidation of 85 carboxylic acids to resin-bound dipeptide derivs. are also given, along with reactivity ratios for solid-phase peptide coupling of 25 N-protected amino acids. Thus, 121 sublibraries I, prepd. by

L4 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
systematically varying R1 (and X and Y), R2, and R3 were prepd. via solid-phase peptide coupling of a tryptophan or (benzothienyl)alanine deriv. (variables R1, X, and Y) to a benzhydrylamine resin, coupling of another amino acid residue (variable R2), coupling of a carboxylic acid residue (variable R3), POC13-induced ring closure, and HF resin cleavage. All 121 prepd. sublibraries were tested for antimicrobial activity and .mu.-opioid receptor binding.  
IT 210982-44-8BD, combinatorial library derivs. 210983-86-IDP, combinatorial library derivs.  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and biol. activity of imidazopyridindole and imidazopyridobenzothiophene combinatorial libraries)  
RN 210982-44-8 CAPLUS  
CN 5H-Imidazo[1',5':1,2]pyrido[3,4-b]indole-5-carboxamide, 6,11-dihydro-1-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 210983-86-1 CAPLUS  
CN [1]Benzothieno[2,3-c]imidazo[1,5-a]pyridine-5-carboxamide, 5,6-dihydro-1-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1596:358249 CAPLUS  
DOCUMENT NUMBER: 125:75343  
TITLE: Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 aro, P450 17 and P450 TxA2  
AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber, Dorothea; Vaeckter, Gerald A.; Gruen, Gertrud L.; Sergejew, Tom F.  
CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ. Saarlandes, Saarbruecken, D-66041, Germany  
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(5), 251-261  
CODEN: ARPHAS; ISSN: 0365-6233  
PUBLISHER: VCH  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralone, tetralin, and dihydronaphthalenes bearing of OCH3 substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-spacer between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 aro (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 TxA2 (citratated human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 acc (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compds. were examd. in Sprague Dawley rats regarding P 450 TxA2 inhibition, redn. of plasma testosterone concn., antiuterotropic activity (inhibition of the uterotrophic activity of androstenedione), redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent new azole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 aro and/or P 450 17 were found: 7-OCH3-2-(imidazol-4-ylmethyl)-1-tetralone (I) and 7-OCH3-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 aro in vitro know so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH3 deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 TxA2, whereas 7-OCH3-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH3-2-(imidazol-1-yl)-3,4-dihydronaphthalene addnl. show strong inhibition of P 450 aro and P 450 17. Structure-activity relations are discussed. Regarding the other steroidogenic P 450 enzymes as well as corticosterone formation, the compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concns. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 aro frazole. The compds. show activity in the aforementioned in vivo tests.  
IT 157058-44-1P 157058-45-2P 157058-46-3P 157058-47-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological


L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)  
RN 157058-44-1 CAPLUS  
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-45-2 CAPLUS  
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 157058-46-3 CAPLUS  
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS  
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-52-1P 157058-53-2P 157058-54-3P 178880-06-3P


L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)  
RN 157058-52-1 CAPLUS  
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS  
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS  
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178880-06-3 CAPLUS  
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 157058-54-3  
CMF C15 H18 N2 O

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CM 2

CRN 144-62-7  
CHF C2 H2 O4

L4 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1996:97011 CAPLUS  
DOCUMENT NUMBER: 124:202093  
TITLE: Novel nonprostanoid prostacyclin (PGI2) mimetics with heterocyclic moiety  
AUTHOR(S): Nagao, Yuuki; Takahashi, Kanji; Torisu, Kazuhiko; Kondo, Kigen; Hamanaka, Nobuyuki  
CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan  
SOURCE: Heterocycles (1996), 42(2), 517-23  
CODEN: HETCYM; ISSN: 0385-5414  
PUBLISHER: Japan Institute of Heterocyclic Chemistry  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Structural modification of [[6-[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(2-benzhydryloxyimino)pentyl]-1,2,3,4-tetrahydro-5-naphthyl]oxy]acetic acid, previously identified as a PGI2 agonist without a PG skeleton, was examined. Such analogs were for example, [[6-[[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid or [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid. Conversion of the oxime moiety in [[6-[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid to a pyrazole led to [[6-[[4-(diphenylmethyl)-1H-pyrazol-1-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(4-benzhydryloxyimino)pentyl]-1,2,3,4-tetrahydro-5-naphthyl]oxy]acetic acid] which strongly inhibited ADP-induced aggregation of human platelets in vitro.

IT 150559-29-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of [[[[[(phenylmethoxy)imino]alkyl]naphthalenyl]oxy]acetate analogs as nonprostanoid prostacyclin mimetics)

RN 150559-29-8 CAPLUS

CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:827732 CAPLUS  
DOCUMENT NUMBER: 124:202093  
TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV. [Erratum to document cited in CA123:198689]  
AUTHOR(S): Hamanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Tokumoto, H.; Kondo, K.  
CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan  
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(18), 2179  
CODEN: BMCLEB; ISSN: 0960-894X  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The errors were not reflected in the abstr. or the index entries.

IT 150559-29-8  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(PGI2 agonist activity of (Erratum))

RN 150559-29-8 CAPLUS

CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 1995:612212 CAPLUS  
DOCUMENT NUMBER: 123:198691  
TITLE: Medetomidine analogs as .alpha.-adrenergic agonists  
AUTHOR(S): Amemiya, Yoshiya; Hus, Fulian; Shams, Gamal; Feller, Dennis R.; Venkataraman, B. V.; Patil, Popat N.; Miller, Duane D.  
CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA  
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 403-10  
CODEN: EJPSBZ; ISSN: 0301-5068  
PUBLISHER: National Information and Documentation Centre  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 123:198691

AB Recently, it has been reported that medetomidine is a new 4-substituted imidazole analog possessing selective and potent .alpha.-2-adrenergic properties. It has been shown that it reduces blood pressure, heart rate and saliva secretion. At the present time is sedative and hypotensive effects seem to be manifest in the same dose range. We have initiated a program to see if it is possible to sep. these activities with analogs of medetomidine. The initial studies have been directed at procedures for the conversion of the imidazoles, a common structure of .alpha.-adrenergic drugs, to the corresponding imidazoles. It was found that 2-substituted and 2,4-disubstituted imidazoles can easily be converted into imidazoles using 10% Pd/C in refluxing toluene, while in some instances there are some difficulties with the conversion of 4-substituted imidazoles to the imidazoles. The synthesis of 1- or 2-(2-or 4-imidazolylmethyl)naphthalene analogs of medetomidine are also described.


IT 127967-88-SP  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. of 4-substituted imidazoles)

RN 127967-88-5 CAPLUS

CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1995:612188 CAPLUS  
 DOCUMENT NUMBER: 123:111932  
 TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs of .alpha.- and .beta.-naphthalene  
 AUTHOR(S): Amemiya, Yoshiya; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl  
 CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA  
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 91-112  
 CODEN: EJPSBZ; ISSN: 0301-5068  
 PUBLISHER: National Information and Documentation Centre  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Seven analogs of medetomidine and naphazoline were synthesized and evaluated for their .alpha.1- (aorta) and .alpha.2- (platelet) activities. The analogs were composed of 2- and 4-substituted imidazoles and imidazolines attached through a methylene bridge to either an .alpha.- or .beta.-naphthalene ring system. In general the .alpha.-naphthalene analogs were found to be the most potent inhibitors of platelet aggregation. .alpha.-Naphthalene analogs were partial agonists while the .beta.-naphthalene analogs were antagonists in .alpha.1-adrenergic system (aorta).  
 IT 137967-82-99 166034-65-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (synthesis and adrenergic activities of medetomidine and naphazoline analogs)  
 RN 137967-82-9 CAPLUS  
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 166034-65-7 CAPLUS  
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 137967-88-5  
 CMF C15 H14 N2

L4 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1995:598392 CAPLUS  
 DOCUMENT NUMBER: 123:198689  
 TITLE: Molecular design of novel PG12 agonists without PG skeleton. IV  
 AUTHOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Nagao, Yuuki; Torisu, Kazuhiko; Tokumoto, Hidekado; Kondo, Kigen  
 CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(10), 1083-6  
 CODEN: BMCLES; ISSN: 0960-894X  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




I

AB The synthesis and biol. evaluation of a novel series of di- or tetrahydronaphthalen-5-oxyacetic acid derivs. with a 4-benzhydrylpyrazolyl group is described. Among these compds., I has been identified as a highly potent PG12 agonist with an exceptionally long in vivo duration of action.  
 IT 150559-29-8  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (PG12 agonist activity of)  
 RN 150559-29-8 CAPLUS  
 CN Acetic acid, [[6-[[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2

CRN 144-62-7  
 CMF C2 H2 O4




IT 137967-88-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis and adrenergic activities of medetomidine and naphazoline analogs)  
 RN 137967-88-5 CAPLUS  
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1995:513524 CAPLUS  
 DOCUMENT NUMBER: 122:265379  
 TITLE: Preparation of (cyanobenzyl)azole derivatives as aromatase inhibitors  
 INVENTOR(S): Shibata, Tomoyuki; Sugimura, Yukio; Tanzawa, Kazuhiko; Takahashi, Masaaki; Kobayashi, Tomowo; Mitsuhashi, Yoshihiro  
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: FIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9408973	A1	19940428	WO 1993-JP1509	19931020
W: AU, CA, CZ, FI, HU, KR, NO, NZ, RU, US				
W: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9352855	A1	19940509	AU 1993-52855	19931020
JP 06263742	A2	19940920	JP 1993-261438	19931020
PRIORITY APPLN. INFO.:			JP 1992-283177	19921021
			WO 1993-JP1509	19931020


 OTHER SOURCE(S): MARPAT 122:265379  
 GI



I




II




III

AB The title compds. (I; R1 = imidazolyl, triazolyl or tetrazolyl each of which may be substituted by Me and/or Et; R2 = naphthyl, phenanthryl or anthryl each of which may be substituted by substituent(s) selected from C1-4 alkyl, C1-4 alkoxy, C1-6 acyloxy, arom. acyloxy, OH, trialkyl, C1-4 acylamino, alkoxyalkoxy, alkoxyacyloxy, and trialkylsilyloxy; R3 = H, Me, cyano), useful for the treatment of breast cancer, are prepd. Thus, 2-bromo-6-methoxynaphthalene was treated with BuLi in hexane and THF at

L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 -78.degree. followed reaction with a soln. of p-cyanobenzaldehyde in THF at -78.degree. gave p-cyano- $\alpha$ -(6-methoxynaphthalen-2-yl)benzyl alc. which was stirred with SOCl<sub>2</sub> in CH<sub>2</sub>Cl<sub>2</sub> at room temp. for 1 h to give p-cyano- $\alpha$ -(6-methoxynaphthalen-2-yl)benzyl chloride. The latter chloride was dissolved in MeCN and refluxed with imidazole overnight to give, after silica gel chromatog. and acidification with HCl, title compd. (II.HCl) which in vitro showed IC<sub>50</sub> of 3.7 nM against aromatase. Hard capsule, tablet, injection and suspension formulations contg. [p-cyanobenzyl]tetrazole deriv. (III.HCl) were described.  
 IT 162573-42-4P 162573-46-8P 162573-58-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of (cyanobenzyl)azole deriv. as aromatase inhibitor and anticancer agent for breast cancer)  
 RN 162573-42-4 CAPLUS  
 CN Benzonitrile, 4-((1H-imidazol-4-yl-2-naphthalenyl)methyl)- (9CI) (CA INDEX NAME)




RN 162573-46-8 CAPLUS  
 CN Benzonitrile, 4-((1H-imidazol-4-yl-9-phenanthrenyl)methyl)- (9CI) (CA INDEX NAME)



RN 162573-58-2 CAPLUS  
 CN Benzonitrile, 4-((1H-imidazol-4-yl-2-naphthalenyl)methyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1594:534112 CAPLUS  
 DOCUMENT NUMBER: 121:134112  
 TITLE: Preparation of imidazolylmethylenetetralones and analogs as aromatase inhibitors  
 INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton  
 PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan  
 SOURCE: PCT Int. Appl., 29 pp. CODEN: FIKXU2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940414	WO 1993-JP1433	19931006
W: AU, BB, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPLN. INFO.: JP 1992-267130 A 19921006				
WO 1993-JP1433 W 19931006				
OTHER SOURCE(S): MARPAT 121:134112				
GI				




AB The title compds. I [A represents hydrogen, Cl-C4 lower alkoxy, nitro or Cl-C4 lower alkoxy carbonyl; when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, Z represents hydrogen and the broken line represents an arbitrary bond; when X represents hydrogen, Y and Z are combined together to represent a single bond; n represents an integer of 0 or 1] are prepd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H<sub>2</sub>SO<sub>4</sub> was heated for 20 h at 80-90.degree. to give, after workup, (E)-2-(4-imidazolylmethylene)-1-tetralone (II). II in vitro showed IC<sub>50</sub> of 0.260  $\mu$ M against aromatase.  
 IT 157058-44-1P 157058-45-2P 157058-46-3P  
 157058-47-4P 157058-52-1P 157058-53-2P  
 157058-54-3P 157058-55-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as aromatase inhibitor)  
 RN 157058-44-1 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl


L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 157058-45-2 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-((1H-imidazol-4-yl)methyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS  
 CN 1H-imidazole, 4-((1,2,3,4-tetrahydro-2-naphthalenyl)methyl)- (9CI) (CA INDEX NAME)




RN 157058-53-2 CAPLUS  
 CN 1H-imidazole, 4-((1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(9CI) (CA INDEX NAME)




RN 157058-54-3 CAPLUS  
CN 1H-imidazole, 4-((1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl)-  
(9CI) (CA INDEX NAME)




RN 157058-55-4 CAPLUS  
CN 1H-imidazole, 4-((1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl)-  
(9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 150559-29-8 CAPLUS  
CN Acetic acid, [[6-[[2-((diphenylmethyl)-1H-imidazol-4-yl)methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:671157 CAPLUS  
DOCUMENT NUMBER: 119:271157  
TITLE: Fused benzeneoxacyclic acid derivative PGI2 receptor agonists  
INVENTOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Tokumoto, Hidekado  
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 110 pp.  
CODEN: EPXKDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 548949	A2	19930630	EP 1992-121898	19921223
EP 548949	A3	19931006		
EP 548949	B1	19970917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 05178832	A2	19930720	JP 1991-360502	19911227
JP 07025854	A2	19950127	JP 1992-209587	19920714
US 5461045	A	19951024	US 1992-912999	19920714
CA 2073917	AA	19940116	CA 1992-2073917	19920715
CA 2085844	AA	19930628	CA 1992-2085844	19921218
AT 158282	E	19971015	AT 1992-121898	19921223
ES 2108076	T3	19971216	ES 1992-121898	19921223
US 5389666	A	19950214	US 1992-997492	19921228
JP 07145037	A2	19950606	JP 1992-360608	19921228
US 5589496	A	19961231	US 1994-334395	19941103
US 5849919	A	19981215	US 1996-722456	19960927
US 5962439	A	19991005	US 1998-168424	19981007
PRIORITY APPLN. INFO.:			JP 1991-360502	19911227
			JP 1992-209587	19920714
			US 1992-997492	19921228
			US 1994-334395	19941103
			US 1996-722456	19960927


OTHER SOURCE(S): MARPAT 119:271157  
GI For diagram(s), see printed CA issue.  
AB The title compds. I [A = (un)substituted heterocyclyl; B = alkylene, alkenylene; ring D = carbocyclic ring; R1 = HO, C1-12 alkoxy, (un)substituted amino], which demonstrate PGI2 receptor agonist activity and are useful in the treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer, or hypertension (no data), are prepd. and I-contg. formulations presented. Thus, pyrazole deriv. II was prepd. which demonstrated 50% inhibitory concn. against human blood platelet aggregation of 0.043 .mu.M in human blood-derived. platelet-rich plasma.  
IT 150558-87-5 150559-29-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(PGI2 receptor agonist activity of)  
RN 150558-87-5 CAPLUS  
CN Acetic acid, [[5,6,7,8-tetrahydro-6-((1H-imidazol-4-ylmethyl)-1-naphthalenyl)oxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:649949 CAPLUS  
DOCUMENT NUMBER: 119:249949  
TITLE: Preparation of imidazole derivatives as interleukin 1 inhibitors and antiphlogistics  
INVENTOR(S): Ueno, Yoshihide; Masumori, Hiroaki; Saji, Kitao  
PATENT ASSIGNEE(S): Sumitomo Pharma, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.  
CODEN: JXKXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05155882	A2	19930622	JP 1991-348294	19911203
PRIORITY APPLN. INFO.:			JP 1991-348294	19911203

OTHER SOURCE(S): MARPAT 119:249949  
GI For diagram(s), see printed CA issue.  
AB The title deriva. I [A = lower alkylene; M = arom. hydrocarbon ring, thiophene; D = O, CO, CH(OR5), C(NOR5), CH(NR5)2], NR5, single bond; R1 = H, halo; R2 = lower alkyl or alkenyl, (un)substituted Ph, (un)substituted cycloalkyl, (un)substituted thienyl; R3 = N-contg. heterocyclyl; R4, R5 = H, lower alkyl; when D is single bond then R2 is lower alkyl] or their acid salts are prepd. as interleukin 1 inhibitors and antiphlogistics. A mixt. of 3-(2-fluoro-4-biphenyl)-1-(4-pyridyl)carbonyl)amino-2-butanone (prepd. from fluorobiphenol in 4 steps), and NH4Ac was heated at 140-150.degree. for 4 h to give 44% 4-(1-(2-fluoro-4-biphenyl)ethyl)-2-(4-pyridyl)imidazole-HCl. I inhibited growth of interleukin 1.  
IT 150972-40-0P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of. as interleukin 1 inhibitor and antiphlogistics)  
RN 150972-40-0 CAPLUS  
CN 2-Naphthalenol, 6-[1-[2-(4-pyridinyl)-1H-imidazol-4-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L4 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1992:106173 CAPLUS  
 DOCUMENT NUMBER: 116:106173  
 TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs  
 AUTHOR(S): Amemiya, Yoshiya; Hong, Seoung S.; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl; Feller, Dennis R.; Hsu, Fu Lian; Miller, Duane D.  
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA  
 SOURCE: Journal of Medicinal Chemistry (1992), 35(4), 750-5  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB Analogs I-III (R = 1-naphthyl, 2-naphthyl; R1 = H, Me) of medetomidine and naphazoline were synthesized and evaluated for their .alpha.1 (aorta) and .alpha.2 (platelet) activities. In general the 1-naphthalene analogs were the most potent inhibitors of epinephrine-induced platelet aggregation. Of considerable interest was the fact that I-III (R = 1-naphthyl) were antagonists in an .alpha.1-adrenergic system (aorta). Thus, appropriately substituted naphthalene analogs of medetomidine and naphazoline provide a spectrum of .alpha.1-agonist, .alpha.1-antagonist, and .alpha.2-antagonist activity.


IT 137967-82-9P 137967-88-5P  
 RL: SPN (Synthetic preparation); PREF (Preparation) (prep. and adrenergic activity of)  
 RN 137967-82-9 CAPLUS  
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 137967-88-5 CAPLUS  
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 The aggregation but blocked the aggregation induced by epinephrine. The affinity of naphazoline for the .alpha.2-adrenoceptor was 1100 nmol/L. The IC50 of medetomidine for platelet anti-aggregatory effect was 3300 nmol/L, which compares favorably with other imidazoline type of blockers of platelet aggregations. Sympathomimetic vasoconstrictor actions and platelet aggregation effects of these compds. can be dissociated. Some vasoconstrictors were antiaggregatory. The structure-activity relationships of the two receptor systems, namely rat aorta (.alpha.1) and platelets (.alpha.2), are discussed.

IT 137967-88-5  
 RL: BIOL (Biological study)  
 (.alpha.-adrenoceptors of aorta and human platelets interaction with, structure in relation to)  
 RN 137967-88-5 CAPLUS  
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1992:15364 CAPLUS  
 DOCUMENT NUMBER: 116:15364  
 TITLE: Structure-activity studies of new imidazolines on adrenoceptors of rat aorta and human platelets  
 AUTHOR(S): Venkataraman, B. V.; Shams, G.; Hamada, A.; Amemiya, Y.; Tantishaiyakul, V.; Hsu, F.; Fashempour, J.; Romstedt, K. J.; Miller, D. D.; et al.  
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA  
 SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1991), 344(4), 454-63  
 CODEN: NSAFPC; ISSN: 0028-1298  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB Potencies of new arom. substituted fluoro or iodo analogs of catecholimidazoline (I) on functional responses in rat aorta (.alpha.1) and platelets (.alpha.2) were quantified. When compared either on the basis of EC50 or the dissociation constant (KA), 5-fluorocatecholimidazoline was as potent as the ref. .alpha.1-adrenoceptor agonist, phenylephrine in the vascular tissue. The max. contraction of aorta produced by the fluoro analog was, however, 17% higher than that of phenylephrine. The time required for 1/2 relaxation of the tissue after 5-fluoro hydroxy imidazoline was at least twice as long as that of the phenylephrine. The catechol moiety as well as fluorine substitution at the crit. 5-position of the arom. ring is essential for higher .alpha.1 adrenoceptor-mediated potency. As compared to the fluoro analogs, the adrenoceptor-mediated potencies of iodo-analogs were relatively weak on vascular tissue. Naphazoline and its analogs were partial agonists on vascular tissue with dissociation constants which ranged from 110 to 2600 nmol/L. Imidazole analogs (II, R = naphthyl or xylene), were generally less potent agonist than the imidazolines by one order of magnitude. The vascular effects of all agonists were competitively blocked by prazosin with KB values which ranged from 0.04 to 0.48 nmol/L. Since the variation in KB values were within normal limits, the action of new imidazolines on rat aorta appears to be mediated mainly by the activation of the .alpha.1-adrenoceptor. Prazosin 10 nmol/L abolished the vascular response of some partial agonists. This indicates a slightly different mode of interaction of agonists with the transduction process. Carbon 4-substituted imidazolines produced little or no .alpha.1 adrenoceptor-mediated intrinsic activity, but competitive receptor blocking potency was comparable to that of phentolamine. Medetomidine was a partial agonist on the rat aorta with a KA of 260 nmol/L. When investigated as a blocker, the KB of medetomidine against phenylephrine was approx. 5600 nmol/L. The variation in the latter value was high. In acetylsalicylic acid-treated human platelets, the .alpha.2-adrenoceptor-mediated aggregatory effect of all fluoro analogs was weak. Iodo or naphazoline analogs did not initiate platelet

L4 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1991:623482 CAPLUS  
DOCUMENT NUMBER: 115:223482  
TITLE: Use of 5-HT3 receptor antagonists for treatment of  
panic disorders, agoraphobia, or obsessive compulsive  
disorders  
INVENTOR(S): Azcona, Alberto  
PATENT ASSIGNEE(S): Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.,  
Austria; Sandoz-Patent-G.m.b.H.; Sandoz A.-G.  
SOURCE: PCT Int. Appl., 35 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9012569	A1	19901101	WO 1990-EP540	19900406
W: AU, CA, JP, KR, US				
FW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2031214	AA	19901022	CA 1990-2031214	19900406
AU 9054158	A1	19901116	AU 1990-54158	19900406
AU 631632	B2	19921203		
EP 422154	A1	19910417	EP 1990-905482	19900406
EP 422154	B1	19931201		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 03505881	T2	19911219	JP 1990-505770	19900406
JP 06069963	B4	19940907		
AT 97803	E	19931215	AT 1990-905482	19900406
ES 2061024	T3	19941201	ES 1990-905482	19900406
ZA 9003015	A	19911224	ZA 1990-3015	19900420
US 5530008	A	19960625	US 1994-187413	19940124

PRIORITY APPLN. INFO.: GB 1989-9147 19890421  
GB 1989-16602 19890720  
EP 1990-905482 19900406  
WO 1990-EP540 19900406  
US 1990-635156 19901219


AB 5-HT3 receptor antagonists are useful in treating panic disorders and/or agoraphobia or obsessive compulsive disorders. Formulations for tablets, i.v. solns. and capsules are presented.

IT 135716-73-3

RL: BIOL (Biological study)  
(5-HT3 receptor antagonist)

RN 135716-73-3 CAPLUS

CN 1(2H)-Phenanthrene, 3,4-dihydro-2-[(5-methyl-1H-imidazol-4-yl)methyl]-  
(9CI) (CA INDEX NAME)




L4 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1990:198377 CAPLUS  
DOCUMENT NUMBER: 112:198377  
TITLE: Preparation and formulation of imidazole derivatives  
as 5-HT3 receptor antagonists  
INVENTOR(S): North, Peter Charles; Oxford, Alexander William;  
Coates, Ian Harold  
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK  
SOURCE: Eur. Pat. Appl., 12 pp.  
CODEN: EPKXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 336759	A1	19891011	EP 1989-303415	19890406
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 02049772	A2	19900220	JP 1989-87841	19890406
US 5116984	A	19920526	US 1989-333967	19890406

PRIORITY APPLN. INFO.: GB 1988-8085 19880407  
GB 1988-8086 19880407

OTHER SOURCE(S): MARPAT 112:198377  
GI



AB Title compds. I (R1, R2 = H, halo, HO, Cl-4 alkoxy, Cl-4 alkyl, Cl-4 alkythio, R3R4N, R3, R4 = H, Cl-4 alkyl, R3R4N = satd. 5-7-membered ring; A = CH, N; Im = substituted imidazolyl; n = 1-3) and physiol. acceptable salts and solvates thereof, potent and selective antagonists of 5-HT3 receptors and useful, e.g., in treatment of psychotic disorders, anxiety, and nausea and vomiting (no data), are prepd. 1,2-Dihydro-3-[[5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]methylene]-4(3H)-phenanthrene (prepn given) was dehydrogenated over Pd/C to give I (R1, R2 = H; A = CH; Im = 5-methylimidazol-4-yl; n = 2) which was converted to the maleate. Tablet and injection formulations were given.

IT 126737-68-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as 5-HT antagonist)

RN 126737-68-6 CAPLUS


CN 4(1H)-Phenanthrene, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-,  
(2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CN 1

CRN 126737-65-3  
CMF C19 H18 N2 O

L4 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




IT 126737-65-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as HT3-receptor antagonist)

RN 126737-65-3 CAPLUS


CN 4(1H)-Phenanthrene, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-  
(9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1990:139033 CAPLUS  
 DOCUMENT NUMBER: 112:139033  
 TITLE: Preparation of imidazole derivatives as drugs  
 INVENTOR(S): Kihara, Noriaki; Tomino, Ikuo; Tan, Hiroaki; Takei, Mitsusachi  
 PATENT ASSIGNEE(S): Mitsui Petrochemical Industries, Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
 CODEN: JK00AF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01242571	A2	19890927	JP 1988-65731	19880322
PRIORITY APPLN. INFO.:			JP 1988-65731	19880322
OTHER SOURCE(S):		MARPAT 112:139033		

GI




AB The title derivs. I or II (R1 = H, Ph; R2-R5 = H, OH, lower alkyl, lower alkoxy, lower alkylamino, halo; R2-R5 may be bonded to from rings; R6, R7 = H, lower alkyl, halo; X = O, S), useful as cerebral function improves, antihypertensives, diuretics, etc. (no data), are prepd. by acid-catalyzed reaction of (hydroxymethyl)imidazoles III or their acid salts with benzenes IV or 5-membered heterocycle V. Thus, aq. III.HCl (R1 = H) was treated with 1,3,5-C6H3Me3 and 4-MeC6H4SO3H at 170.degree. for 7 h to give 761 I (R1 = R2 = H, R3-R5 = 2,4,6-Me3).

IT 125883-69-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of, as drug)

RN 125883-69-4 CAPLUS



CN 1H-imidazole, 4-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1979:168771 CAPLUS  
 DOCUMENT NUMBER: 90:168771  
 TITLE: Photochemical reactions. Photochemistry of N-acylimidazoles. V. Photolysis of the N-acylimidazoles of dehydroabietic acid and of 13-deisopropyl-10-epi-dehydroabietic acid  
 Iwasaki, Shigeo  
 Org.-Chem. Lab., ETH, Zurich, Switz.  
 Helvetica Chimica Acta (1978), 61(8), 2843-50  
 CODEN: HCACAV; ISSN: 0018-019X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI

L4 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




AB Irradn. of I gave no Type II elimination, but gave II and III by migration of the imidazolylcarbonyl group, probably via a cyclobutanol intermediate. Similarly, irradn. of IV gave only a small amt. of Type II fragmentation, the main products being derived from .gamma.-H abstraction.

IT 69634-29-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)

RN 69634-29-3 CAPLUS


CN Methanone, 1H-imidazol-4-yl[4b,5,6,7,8,8a,9,10-octahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1973:515495 CAPLUS  
 DOCUMENT NUMBER: 79:115495  
 TITLE: Synthesis of small molecule catalysts. Model for the active site of ribonuclease-A  
 AUTHOR(S): Algieri, Aldo A.  
 CORPORATE SOURCE: Cornell Univ., Ithaca, NY, USA  
 SOURCE: (1973) 116 pp. Avail.: Univ. Microfilms, Ann Arbor, Mich., Order No. 73-14,715  
 From: Diss. Abstr. Int. B 1973, 33(12) (Pt. 1), 5722  
 DOCUMENT TYPE: Dissertation  
 LANGUAGE: English  
 AB Unavailable  
 IT 49738-45-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (as model for the active site of ribonuclease A)  
 RN 49738-45-6 CAPLUS  
 CN 1H-imidazole-4-ethanamine, N-[[3-(1H-imidazol-4-ylmethyl)-1-naphthalenyl]methyl]-, conjugate diacid (9CI) (CA INDEX NAME)



● 2 H<sup>+</sup>

L4 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1972:501463 CAPLUS  
 DOCUMENT NUMBER: 77:101463  
 TITLE: Voges-Proskauer reaction. II. Structure of a pigment from the diacetyl reaction of 1-benzyl-1-methylguanidine  
 AUTHOR(S): Nishimura, Tamio; Yamazaki, Chiji; Ueno, Tetsuro; Kitajima, Shinichi; Ishige, Koichi  
 CORPORATE SOURCE: Sch. Hyg. Sci., Kitasato Univ., Tokyo, Japan  
 SOURCE: Bulletin of the Chemical Society of Japan (1972), 45(6), 1782-5  
 CODEN: BCSJAB; ISSN: 0009-2673  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A pigment formed by the reaction of 1-benzyl-1-methylguanidine was isolated as reddish purple prisms. The reduced pigment was colorless and rapidly converted back to the original pigment on exposure to the air. On the basis of ir, NMR, and mass spectral evidence, the structures of the pigment and the reduced form were established to be 2-(N-benzyl-N-methylamino)-4-methyl-5-(1-oxo-1,2-dihydro-2-naphthylidenemethyl)imidazole and 5-(1-hydroxy-2-naphthylmethyl)imidazole, resp.  
 IT 37842-56-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 37842-56-1 CAPLUS  
 CN 1-Naphthalenol, 2-[[5-methyl-2-[methyl(phenylmethyl)amino]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

150.78

299.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-20.83

-20.83

STN INTERNATIONAL LOGOFF AT 07:05:47 ON 03 FEB 2003

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:358249 CAPLUS

DOCUMENT NUMBER: 125:75343

TITLE: Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17 and P450 TxA2

AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber, Dorothea; Waechter, Gerald A.; Gruen, Gertrud L.; Sergejew, Tom F.

CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ. Saarlandes, Saarbruecken, D-66041, Germany

SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(5), 251-261

CODEN: ARPMAS; ISSN: 0365-6233

PUBLISHER: VCH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing of OCH3 substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-spacer between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 arom (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 TxA2 (citratated human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 scc (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compds. were examd. in Sprague Dawley rats regarding P 450 TxA2 inhibition, redn. of plasma testosterone concn., antiuterotropic activity (inhibition of the uterotrophic activity of androstenedione), redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent new azole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 arom and/or P 450 17 were found; 7-OCH3-2-(imidazol-4-ylmethylene)-1-tetralone (I) and 7-OCH3-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 arom in vitro know so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH3 deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 TxA2, whereas 7-OCH3-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH3-2-imidazol-1-yl-3,4-dihydronaphthalene addnl. show strong inhibition of P 450 arom and P 450 17. Structure-activity relations are discussed. Regarding the other steroidogenic P 450 enzymes as well as corticosterone formation, the compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concns. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 arom fadrozole. The compds. show activity in the aforementioned in vivo tests.

IT 157058-44-1P 157058-45-2P 157058-46-3P


157058-47-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-45-2 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-52-1P 157058-53-2P 157058-55-4P  
178880-06-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and evaluation ofazole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-52-1 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 157058-53-2 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178880-06-3 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 157058-54-3


CMF C15 H18 N2 O



CM 2

CRN 144-62-7

CMF C2 H2 O4



L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:534112 CAPLUS

DOCUMENT NUMBER: 121:134112

TITLE: Preparation of imidazolylmethylenetetralones and analogs as aromatase inhibitors

INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton

PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940414	WO 1993-JP1433	19931006
W: AU, BB, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPLN. INFO.:			JP 1992-267130	A 19921006
			WO 1993-JP1433	W 19931006
OTHER SOURCE(S):		MARPAT 121:134112		
GI				




AB The title compds. I [R represents hydrogen, C1-C4 lower alkoxy, nitro or C1-C4 lower alkoxy carbonyl; when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, Z represents hydrogen and the broken line represents an arbitrary bond; when X represents hydrogen, Y and Z are combined together to represent a single bond; n represents an integer of 0 or 1] are prepd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H<sub>2</sub>SO<sub>4</sub> was heated for 20 h at 80-90.degree. to give, after workup, (E)-2-(4-imidazolylmethylene)-1-tetralone (II). II in vitro showed IC<sub>50</sub> of 0.260 .mu.M against aromatase.

IT **157058-44-1P 157058-45-2P 157058-46-3P**  
**157058-47-4P 157058-52-1P 157058-53-2P**  
**157058-54-3P 157058-55-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of, as aromatase inhibitor)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




$R^1$  is Oxo  
 $R^2$  &  $R^3$  form unsaturated ring ✓  
 $R_6 = H$   
 $s=0$   
 $t=0$


RN 157058-45-2 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy-  
 (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy-  
 (9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS  
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-  
 (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS  
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA  
 INDEX NAME)






RN 157058-53-2 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]-  
(9CI) (CA INDEX NAME)



RN 157058-54-3 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-  
(9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-  
(9CI) (CA INDEX NAME)

